HLA-Haploidentical Bone Marrow Transplantation for H Nonmyeloablative Conditioning and High-Dose, Posttra

Biology of Blood and Marrow Transplantation

14, 641-650

DOI: 10.1016/j.bbmt.2008.03.005

Citation Report

#	Article	IF	Citations
1	Current Awareness in Hematological Oncology. Hematological Oncology, 2008, 26, 253-260.	1.7	0
2	Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplantation, 2008, 42, 365-377.	2.4	38
3	Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Experimental Hematology, 2008, 36, 1750-1759.	0.4	12
4	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 1279-1287.	2.0	251
5	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia When a Matched Related Donor Is Not Available. Hematology American Society of Hematology Education Program, 2008, 2008, 412-417.	2.5	26
6	Current and future approaches for control of graft-versus-host disease. Expert Review of Hematology, 2008, 1, 111-128.	2.2	32
7	Unmanipulated or CD34 selected haplotype mismatched transplants. Current Opinion in Hematology, 2008, 15, 561-567.	2.5	27
8	O transplante de cÃ©lulas-tronco hematopoÃ©ticas na infÃ¢ncia: situaÃ§Ã£o atual e perspectivas. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 59-67.	0.7	2
9	Emerging drugs for acute graft-versus-host disease. Expert Opinion on Emerging Drugs, 2009, 14, 219-232.	2.4	5
10	Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplantation, 2009, 43, 477-480.	2.4	10
11	Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplantation, 2009, 43, 969-970.	2.4	9
12	Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology, 2009, 6, 638-647.	27.6	675
13	Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation. Tissue Antigens, 2009, 74, 494-498.	1.0	14
14	Composite Tissue Allotransplantation: Current Challenges. Transplantation Proceedings, 2009, 41, 3519-3528.	0.6	44
15	Blood and Bone Marrow Transplantation for Acute Myeloid Leukemia. Clinical Leukemia, 2009, 3, E11-E21.	0.2	3
16	Dissociation Between Peripheral Blood Chimerism and Tolerance to Hindlimb Composite Tissue Transplants: Preferential Localization of Chimerism in Donor Bone. Transplantation, 2009, 88, 773-781.	1.0	26
17	Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Current Opinion in Oncology, 2009, 21, 158-161.	2.4	35
18	Pilot Study of a 213Bismuth-Labeled Anti-CD45 mAb as a Novel Nonmyeloablative Conditioning for DLA-Haploidentical Littermate Hematopoietic Transplantation. Transplantation, 2010, 89, 1336-1340.	1.0	14

#	Article	IF	Citations
19	High-dose cyclophosphamide for graft-versus-host disease prevention. Current Opinion in Hematology, 2010, 17, 493-499.	2.5	84
20	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood, 2010, 115, 2136-2141.	1.4	107
21	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood, 2010, 115, 3224-3230.	1.4	346
22	Haploidentical transplantation in children. Blood, 2010, 115, 3420-3421.	1.4	3
23	Who is fit for allogeneic transplantation?. Blood, 2010, 116, 4762-4770.	1.4	93
24	Evaluation of Posttransplant Methotrexate to Facilitate Engraftment in the Canine Major Histocompatibility Complex-Haploidentical Nonmyeloablative Transplant Model. Transplantation, 2010, 90, 14-22.	1.0	1
25	High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunologic Research, 2010, 47, 65-77.	2.9	178
26	High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunologic Research, 2010, 47, 179-184.	2.9	39
27	Haploidentical Transplantation for Leukemia. Current Oncology Reports, 2010, 12, 292-301.	4.0	22
28	Transplante de medula Ã³ssea com doador familiar parcialmente compatÃvel. Revista Brasileira De Hematologia E Hemoterapia, 0, 32, 13-15.	0.7	1
29	Serum Cytokine Profiles at the Onset of Severe, Diffuse Alveolar Hemorrhage Complicating Allogeneic Hematopoietic Stem Cell Transplantation, Treated Successfully with Pulse Intravenous Cyclophosphamide. Acta Haematologica, 2010, 124, 171-175.	1.4	9
30	Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplantation, 2010, 45, 1038-1046.	2.4	120
31	A Preclinical Canine Model for Composite Tissue Transplantation. Journal of Reconstructive Microsurgery, 2010, 26, 201-207.	1.8	19
32	Hematopoietic Stem Cell Transplantation for MDS. Hematology/Oncology Clinics of North America, 2010, 24, 407-422.	2.2	40
33	Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to?. Cytotherapy, 2010, 12, 440-454.	0.7	6
34	Have we made progress in the management of chronic graft-vs-host disease?. Best Practice and Research in Clinical Haematology, 2010, 23, 529-535.	1.7	28
35	Should Methotrexate plus Calcineurin Inhibitors BeÂConsidered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease?. Biology of Blood and Marrow Transplantation, 2010, 16, S18-S27.	2.0	48
36	HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2010, 16, S57-S63.	2.0	37

#	Article	IF	Citations
37	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. Biology of Blood and Marrow Transplantation, 2010, 16, 384-394.	2.0	39
38	Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biology of Blood and Marrow Transplantation, 2010, 16, 482-489.	2.0	260
39	Preservation of Immune Repertoire by Selective Depletion of Haploidentical Grafts. Biology of Blood and Marrow Transplantation, 2010, 16, S68-S74.	2.0	2
40	Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 533-542.	2.0	168
41	NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2010, 16, 1037-1069.	2.0	47
42	Allogeneic hematopoietic cell transplantation: the state of the art. Expert Review of Hematology, 2010, 3, 285-299.	2.2	142
43	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 2011, 118, 6438-6445.	1.4	158
44	Modern Therapy of Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 532-543.	1.6	425
45	Novel Transplant Strategies in Adults with Acute Leukemia. Hematology/Oncology Clinics of North America, 2011, 25, 1319-1339.	2.2	0
46	Clinical management of aplastic anemia. Expert Review of Hematology, 2011, 4, 221-230.	2.2	48
47	Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Practice and Research in Clinical Haematology, 2011, 24, 351-358.	1.7	9
48	Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Practice and Research in Clinical Haematology, 2011, 24, 359-368.	1.7	50
49	Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 197-204.	2.0	58
50	5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 754-758.	2.0	58
51	The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age. Biology of Blood and Marrow Transplantation, 2011, 17, 1205-1213.	2.0	7
52	Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution. Biology of Blood and Marrow Transplantation, 2011, 17, 1404-1409.	2.0	128
53	Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1099-1111.	2.0	8
54	Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1537-1545.	2.0	30

#	Article	IF	Citations
55	Vascularized Composite Allotransplantation at a Crossroad. Transplantation Proceedings, 2011, 43, 3501-3503.	0.6	6
56	Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Current Opinion in Oncology, 2011, 23, 681-691.	2.4	12
57	Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood, 2011, 118, 2609-2617.	1.4	94
58	A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood, 2011, 118, 4732-4739.	1.4	71
59	Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood, 2011, 118, 1197-1207.	1.4	121
60	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood, 2011, 118, 282-288.	1.4	549
61	MCD & HHV-8 viral load. Blood, 2011, 118, 217-218.	1.4	1
62	Now everyone has a donor for HSCT. Blood, 2011, 118, 218-218.	1.4	6
63	The great debate: haploidentical or cord blood transplant. Bone Marrow Transplantation, 2011, 46, 323-329.	2.4	41
64	Alternative donor hematopoietic stem cell transplantation: current concepts. ISBT Science Series, 2011, 6, 328-331.	1.1	0
65	Haploidentical hematopoietic transplantation: current status and future perspectives. Blood, 2011, 118, 6006-6017.	1.4	155
66	Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 2011, 60, 757-769.	4.2	26
67	Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplantation, 2011, 46, 539-544.	2.4	15
68	Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplantation, 2011, 46, 1012-1013.	2.4	43
69	Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical haematopoietic SCT. Bone Marrow Transplantation, 2011, 46, 1331-1338.	2.4	5
70	Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia, 2011, 25, 880-883.	7.2	18
71	Algorithm for donor selection in 2011. Current Opinion in Hematology, 2011, 18, 401-407.	2.5	10
72	Haploidentical Hematopoietic Stem-Cell Transplantation in Adults. Bone Marrow Research, 2011, 2011, 1-10.	1.7	16

#	Article	IF	Citations
73	Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation with High Dose, Post-Transplantation Cyclophosphamide. Mental Illness, 2011, 3, e15.	0.8	66
74	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012075.	1.3	6
75	Cyclophosphamide-Based In Vivo T-Cell Depletion for HLA-Haploidentical Transplantation in Fanconi Anemia. Pediatric Hematology and Oncology, 2012, 29, 568-578.	0.8	25
76	The Need for Inducing Tolerance in Vascularized Composite Allotransplantation. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	16
77	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Current Opinion in Hematology, 2012, 19, 427-433.	2.5	30
78	Nonmyeloablative Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2012, 18, 457-462.	2.0	19
79	Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Current Opinion in Hematology, 2012, 19, 440-447.	2.5	30
80	Future Trends in Hematopoietic Stem Cell Transplantation. Current Problems in Dermatology, 2012, 43, 165-170.	0.7	5
81	Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay. Bone Marrow Transplantation, 2012, 47, 663-668.	2.4	28
82	The Quest for Transplantation Tolerance: Have We Finally Sipped from the Cup?. Science Translational Medicine, 2012, 4, 124fs5.	12.4	13
83	Haploidentical Stem Cell Transplantation. Hematology/ Oncology and Stem Cell Therapy, 2012, 5, 73-83.	0.9	4
84	New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies. Reviews on Recent Clinical Trials, 2012, 7, 224-237.	0.8	7
85	Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica, 2012, 97, 1523-1531.	3.5	116
86	Related or unrelated donor. Blood, 2012, 119, 2183-2184.	1.4	2
87	HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood, 2012, 120, 4285-4291.	1.4	387
88	Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Annals of the New York Academy of Sciences, 2012, 1266, 161-170.	3.8	51
89	Allogeneic hematopoietic cell transplantation for MDS: For whom, when and how?. Blood Reviews, 2012, 26, 247-254.	5.7	15
90	Pluripotent Stem Cellâ€"Based Cancer Therapy: Promise and Challenges. Science Translational Medicine, 2012, 4, 127ps9.	12.4	49

#	Article	IF	Citations
91	Comparison of Allogeneic Stem Cell Transplantation from Familial-Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2012, 18, 1552-1563.	2.0	39
92	Haploidentical Transplantation: RepurposingÂCyclophosphamide. Biology of Blood and Marrow Transplantation, 2012, 18, 1771-1772.	2.0	18
93	Selective T-Cell Depletion for Haplotype-Mismatched Allogeneic Stem Cell Transplantation. Seminars in Oncology, 2012, 39, 674-682.	2.2	52
94	Graft-Versus-Host Disease: Have We Solved the Problem?. Journal of Clinical Oncology, 2012, 30, 3160-3161.	1.6	7
95	New strategies for haploidentical transplantation. Pediatric Research, 2012, 71, 418-426.	2.3	30
96	Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Review of Hematology, 2012, 5, 409-425.	2.2	26
97	Progress in Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 372-380.	2.0	39
98	Back to the Future: Mismatched Unrelated Donor, Haploidentical Related Donor, or Unrelated Umbilical Cord Blood Transplantation?. Biology of Blood and Marrow Transplantation, 2012, 18, S161-S165.	2.0	38
99	Novel regulatory therapies for prevention of Graft-versus-host disease. BMC Medicine, 2012, 10, 48.	5.5	12
100	Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation. Seminars in Oncology, 2012, 39, 683-693.	2.2	282
101	Prevention of graft-vs.-host disease. Expert Opinion on Pharmacotherapy, 2012, 13, 1737-1750.	1.8	15
102	A Two-Step Approach to Allogeneic Haploidentical Hematopoietic Stem Cell Transplantation. Seminars in Oncology, 2012, 39, 694-706.	2.2	10
103	New Approaches to Graft Engineering for Haploidentical Bone Marrow Transplantation. Seminars in Oncology, 2012, 39, 664-673.	2.2	72
104	Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft-versus-Graft Effects. Biology of Blood and Marrow Transplantation, 2012, 18, 1808-1818.	2.0	1
105	Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial. Biology of Blood and Marrow Transplantation, 2012, 18, 1859-1866.	2.0	250
106	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1835-1844.	2.0	227
109	Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia. Stem Cells, 2012, 30, 1581-1586.	3.2	45
110	Emerging concepts in haematopoietic cell transplantation. Nature Reviews Immunology, 2012, 12, 403-416.	22.7	105

#	Article	IF	Citations
111	Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation. Science Translational Medicine, 2012, 4, 124ra28.	12.4	376
112	The expanding frontier of hematopoietic cell transplantation. Cytometry Part B - Clinical Cytometry, 2012, 82B, 271-279.	1.5	17
113	Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood, 2012, 119, 1972-1980.	1.4	136
114	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 144-152.	2.3	23
115	When matched family donor is not available for blood and marrow transplantationâ€"the Indian dilemma. Apollo Medicine, 2012, 9, 62-67.	0.0	0
116	Unmanipulated HLAâ€mismatched/haploidentical peripheral blood stem cell transplantation for highâ€risk hematologic malignancies. Transfusion, 2012, 52, 1354-1362.	1.6	22
117	Cooking Up Tolerance: Has a New Recipe Been Created?. American Journal of Transplantation, 2012, 12, 1667-1669.	4.7	2
118	Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations. Pediatric Transplantation, 2012, 16, E342-7.	1.0	0
119	Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status. Archivum Immunologiae Et Therapiae Experimentalis, 2012, 60, 31-41.	2.3	5
120	Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2013, 19, 117-122.	2.0	324
121	Effect of HLA mismatch on acute graft-versus-host disease. International Journal of Hematology, 2013, 98, 300-308.	1.6	33
122	Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies. International Journal of Hematology, 2013, 97, 581-598.	1.6	19
123	A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer Chemotherapy and Pharmacology, 2013, 72, 607-618.	2.3	9
124	Longâ€term followâ€up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer, 2013, 119, 978-985.	4.1	224
126	InÂVivo T Cell Costimulation Blockade with Abatacept forÂAcute Graft-versus-Host Disease Prevention: A First-in-Disease Trial. Biology of Blood and Marrow Transplantation, 2013, 19, 1638-1649.	2.0	96
127	Graft-versus-Host Disease: State of the Science. Biology of Blood and Marrow Transplantation, 2013, 19, S102-S108.	2.0	17
128	Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplantation, 2013, 48, 183-185.	2.4	48
129	Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Expert Review of Hematology, 2013, 6, 547-562.	2.2	25

#	Article	IF	Citations
130	Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide. Science Translational Medicine, 2013, 5, 211ra157.	12.4	303
131	Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Annals of Hematology, 2013, 92, 1379-1388.	1.8	33
132	Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S282-S288.	0.4	12
133	Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2013, 19, 1514-1517.	2.0	103
134	Selective Allodepletion: Have We Finally Found the Holy Grail?. Biology of Blood and Marrow Transplantation, 2013, 19, 1413-1414.	2.0	7
135	Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplantation, 2013, 48, 346-350.	2.4	86
136	The current role of <scp>T</scp> cell depletion in paediatric stem cell transplantation. British Journal of Haematology, 2013, 162, 177-190.	2.5	29
137	Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?. Bone Marrow Transplantation, 2013, 48, 338-345.	2.4	13
138	<scp>HLA</scp>â€haploidentical bone marrow transplantation for haematologic malignancies. Internal Medicine Journal, 2013, 43, 734-735.	0.8	0
139	Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Stem Cells, 2013, 31, 592-601.	3.2	84
140	Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, andÂApplications. Biology of Blood and Marrow Transplantation, 2013, 19, 682-691.	2.0	35
141	Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies. Biology of Blood and Marrow Transplantation, 2013, 19, 647-652.	2.0	113
142	Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 602-606.	2.0	87
143	Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease. Experimental Hematology, 2013, 41, 903-911.	0.4	15
144	T-Cellâ€"Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation. Journal of Clinical Oncology, 2013, 31, 1310-1316.	1.6	451
145	Many are Called but Few are Chosen: Under-utilization of Unrelated Donor Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1414-1415.	2.0	5
146	Cellular mechanism for granulocyte-colony stimulating factor in the prevention of graft-versus-host disease in combined bone marrow and peripheral blood transplantation for hematological malignancies: The composition in collection. Transfusion and Apheresis Science, 2013, 48, 3-9.	1.0	8
147	Allogeneic stem cell transplantation for diffuse large B cell lymphoma: Defining the role of allografts. Transfusion and Apheresis Science, 2013, 49, 63-71.	1.0	1

#	Article	IF	Citations
148	Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports, 2013, 8, 132-140.	2.3	11
149	B and T cells in chronic graft-versus-host disease and graft-versus-leukemia. , 2013, , 299-326.		0
150	Stem Cell Transplantation. Klinische Padiatrie, 2013, 225, 94-96.	0.6	5
151	Current status of stem cell therapy in China. International Journal of Hematologic Oncology, 2013, 2, 289-297.	1.6	0
152	Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leukemia and Lymphoma, 2013, 54, 1591-1601.	1.3	40
153	Haploidentical hematopoietic SCT increases graft-versus-tumor effect against renal cell carcinoma. Bone Marrow Transplantation, 2013, 48, 1084-1090.	2.4	1
154	Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 1237-1242.	2.4	13
155	Strategies in Haploidentical Stem Cell Transplantation in Adults. Turkish Journal of Haematology, 2013, 30, 342-350.	0.5	3
156	Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplantation, 2013, 48, 1335-1341.	2.4	22
157	Alternative transplant donor sources. Current Opinion in Oncology, 2013, 25, 173-179.	2.4	16
158	Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. Current Opinion in Hematology, 2013, 20, 115-122.	2.5	11
159	Hematopoietic stem cell transplantation in HIV-1-infected individuals. Current Opinion in Oncology, 2013, 25, 180-186.	2.4	12
160	At the Bench: Preclinical rationale for exploiting NK cells and Î³Î´ T lymphocytes for the treatment of high-risk leukemias. Journal of Leukocyte Biology, 2013, 94, 1123-1139.	3.3	43
161	Evolving Approaches of Hematopoietic Stem Cellâ€“Based Therapies to Induce Tolerance to Organ Transplants: The Long Road to Tolerance. Clinical Pharmacology and Therapeutics, 2013, 93, 36-45.	4.7	38
162	Antiâ€leukaemic activity of a novel haploidenticalâ€transplantation approach employing unmanipulated bone marrow followed by <scp>CD</scp>6â€depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia. British Journal of Haematology, 2013, 162, 802-807.	2.5	6
163	Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro <scp>T</scp>â€cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. European Journal of Haematology, 2013, 91, 304-314.	2.2	55
164	Allogeneic transplantation in the <scp>UK</scp>: an aggregation of marginal gains?. British Journal of Haematology, 2013, 163, 149-159.	2.5	6
165	Haploidentical bone marrow transplants for haematological malignancies using nonâ€myeloablative conditioning therapy and postâ€transplant immunosuppression with cyclophosphamide: results from a single <scp>A</scp>ustralian centre. Internal Medicine Journal, 2013, 43, 191-196.	0.8	14

#	Article	IF	Citations
166	Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10â€year, singleâ€center experience. Transplant Infectious Disease, 2013, 15, 233-242.	1.7	120
167	Haploidentical, unmanipulated, G-CSFâ€“primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood, 2013, 121, 849-857.	1.4	209
168	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood, 2013, 122, 1510-1517.	1.4	104
169	Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1227-1233.	4.9	8
170	Hematopoeitic stem cells allogeneic transplant. Hematologie, 2013, 19, 288-296.	0.0	1
171	History of Hematopoietic Stem Cell Transplantation. , 2014, , 299-312.		0
172	Donor selection in hematopoietic stem cell transplantation. Journal of Hematopoietic Cell Transplantation, 2014, 3, 39-48.	0.1	0
173	Autograft and allograft. Hematologie, 2014, 20, 172-182.	0.0	0
174	Dyskwalifikacja dawcy komÃ³rek krwiotwÃ³rczych w trakcie chemioterapii wysokodawkowanej u biorcy przygotowywanego do transplantacji: propozycja algorytmu postÄ™powania ratunkowego. Acta Haematologica Polonica, 2014, 45, 370-373.	0.3	0
175	Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplantation, 2014, 49, 206-211.	2.4	45
176	Tolerance--Is It Worth It?. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015594-a015594.	6.2	5
177	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. Hematology American Society of Hematology Education Program, 2014, 2014, 21-33.	2.5	31
178	The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplantation, 2014, 49, 55-61.	2.4	36
179	Induction of Tolerance through Mixed Chimerism. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015529-a015529.	6.2	111
180	Stem Cell Transplantation as a Dynamical System: Are Clinical Outcomes Deterministic?. Frontiers in Immunology, 2014, 5, 613.	4.8	25
181	Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplantation, 2014, 49, 895-901.	2.4	45
182	Hematopoietic Stem Cell Transplantation for Patients with Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2014, 28, 1171-1185.	2.2	50
183	Rapamycinâ€resistant effector Tâ€cell therapy. Immunological Reviews, 2014, 257, 210-225.	6.0	18

#	Article	IF	Citations
185	Stem cell transplantation for acute myeloid leukaemia in adults. Memo - Magazine of European Medical Oncology, 2014, 7, 227-230.	0.5	0
186	Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes. Current Opinion in Oncology, 2014, 26, 642-649.	2.4	4
187	Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis. Expert Review of Hematology, 2014, 7, 407-421.	2.2	12
188	Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 440-449.	2.0	88
189	Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2014, 20, 724-729.	2.0	141
190	HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 314-318.	2.0	103
191	Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplantation, 2014, 49, 873-879.	2.4	38
192	Expertsâ€™ considerations on <scp>HLA</scp>â€haploidentical stem cell transplantation. European Journal of Haematology, 2014, 93, 187-197.	2.2	24
193	Thinking Out of the Boxâ€"New Approaches to Controlling GVHD. Current Hematologic Malignancy Reports, 2014, 9, 73-84.	2.3	5
194	Peripheral Blood Hematopoietic Stem Cells for Transplantation of Hematological Diseases from Related, Haploidentical Donors after Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 890-895.	2.0	126
195	Acquired Aplastic Anemia. , 2014, , 685-694.		2
196	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1314-1321.	2.0	36
197	Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkinâ€™s lymphoma. Bone Marrow Transplantation, 2014, 49, 190-194.	2.4	136
198	First-line extracorporeal photochemotherapy for acute GVHD after unmanipulated haploidentical BMT following nonmyeloablative conditioning and post transplantation CY. Bone Marrow Transplantation, 2014, 49, 317-318.	2.4	9
199	Adult adherent stromal cells in the management of graft-versus-host disease. Expert Opinion on Biological Therapy, 2014, 14, 231-246.	3.1	23
200	Feasibility of HLA-Haploidentical Hematopoietic Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Advanced Pediatric Malignancies. Pediatric Hematology and Oncology, 2014, 31, 754-764.	0.8	35
201	Haploidentical versus Matched Donor Stem Cell Transplantations for Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients. Biology of Blood and Marrow Transplantation, 2014, 20, 1875-1876.	2.0	2
202	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency. Biology of Blood and Marrow Transplantation, 2014, 20, 1940-1948.	2.0	84

#	Article	IF	Citations
203	Blood and marrow transplantation for sickle cell disease: Is less more?. Blood Reviews, 2014, 28, 243-248.	5.7	20
204	Desensitization for solid organ and hematopoietic stem cell transplantation. Immunological Reviews, 2014, 258, 183-207.	6.0	54
205	Haploidentical stem cell transplantation for the treatment of leukemia: current status. Expert Review of Hematology, 2014, 7, 635-647.	2.2	24
206	Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplantation, 2014, 49, 1475-1480.	2.4	41
207	Transplantation tolerance: from theory to clinic. Immunological Reviews, 2014, 258, 64-79.	6.0	34
208	Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning. Journal of Clinical Oncology, 2014, 32, 3497-3505.	1.6	234
209	Calcineurin Inhibitorâ€“Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1828-1834.	2.0	51
210	The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Expert Opinion on Pharmacotherapy, 2014, 15, 325-336.	1.8	21
211	Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases, 2014, 59, 473-481.	5.8	201
212	Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances. Bone Marrow Transplantation, 2014, 49, 1070-1075.	2.4	34
213	â€œDesignedâ€•grafts for HLA-haploidentical stem cell transplantation. Blood, 2014, 123, 967-973.	1.4	71
214	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 257-263.	2.0	15
217	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Are We Closer to Knowing Who Needs It?. Current Hematologic Malignancy Reports, 2014, 9, 128-37.	2.3	2
218	Are Alternative Donors Really Still â€œAlternative?â€• Biology of Blood and Marrow Transplantation, 2014, 20, 1463-1464.	2.0	3
219	Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplantation, 2014, 49, 1124-1126.	2.4	24
220	T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplantation, 2014, 49, 999-1008.	2.4	67
221	Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigenâ€“Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study. Biology of Blood and Marrow Transplantation, 2014, 20, 696-704.	2.0	118
222	Peripheral Blood Stem Cells for T Cellâ€“Replete Nonmyeloablative Hematopoietic Transplants Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2014, 20, 598-599.	2.0	3

#	Article	IF	Citations
223	Current and emerging strategies for the prevention of graft-versus-host disease. Nature Reviews Clinical Oncology, 2014, 11, 536-547.	27.6	180
224	Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Therapy, 2014, 21, 337-342.	4.5	35
225	Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 1485-1492.	2.0	43
226	Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts. Biology of Blood and Marrow Transplantation, 2014, 20, 1573-1579.	2.0	259
227	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World Journal of Stem Cells, 2014, 6, 69.	2.8	29
228	ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014065.	1.3	8
229	Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. World Journal of Stem Cells, 2014, 6, 380.	2.8	6
230	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 346-352.	3.5	153
231	Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood, 2014, 124, 2131-2141.	1.4	162
232	Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood, 2014, 124, 334-343.	1.4	125
233	T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood, 2014, 124, 2735-2743.	1.4	171
234	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827.	1.4	165
235	GVHD prophylaxis made safe, easy, and inexpensive. Blood, 2014, 124, 3672-3673.	1.4	4
236	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood, 2015, 125, 2865-2874.	1.4	119
237	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood, 2015, 125, 3024-3031.	1.4	259
238	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood, 2015, 126, 478-485.	1.4	37
239	A maturing understanding of naive T cells. Blood, 2015, 125, 2742-2743.	1.4	0
240	Immunomodulatory Strategies Directed Toward Tolerance of Vascularized Composite Allografts. Transplantation, 2015, 99, 1590-1597.	1.0	9

#	Article	IF	Citations
241	Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques. Clinical and Experimental Immunology, 2015, 181, 491-510.	2.6	8
242	HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Journal of Hematopoietic Cell Transplantation, 2015, 4, 9-22.	0.1	0
243	Immunotherapy in acute myeloid leukemia. Cancer, 2015, 121, 2689-2704.	4.1	30
244	Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance. Transplantation, 2015, 99, 2476-2484.	1.0	2
245	CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015015.	1.3	14
246	Should a More Personalized Approach be Applied to Hematopoietic Stem-Cell Transplantation?. Journal of Stem Cell Research & Therapy, 2015, 05, .	0.3	0
247	Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients. Journal of Clinical Medicine, 2015, 4, 441-459.	2.4	17
248	Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of Clinical Medicine, 2015, 4, 665-695.	2.4	98
249	Alternative Donor Transplantation for Acute Myeloid Leukemia. Journal of Clinical Medicine, 2015, 4, 1240-1268.	2.4	5
250	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 516.	4.8	79
251	Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. Journal of Immunology Research, 2015, 2015, 1-11.	2.2	12
252	Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Korean Journal of Pediatrics, 2015, 58, 199.	1.9	34
253	Progress in Haploidentical Hematopoietic Stem Cell Transplantation. , 2015, , .		0
254	Facilitating cells in tolerance induction for kidney transplantation. Current Opinion in Organ Transplantation, 2015, 20, 57-63.	1.6	12
255	Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies. Bone Marrow Transplantation, 2015, 50, 1092-1097.	2.4	21
256	Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplantation, 2015, 50, 685-689.	2.4	128
257	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplantation, 2015, 50, 1037-1056.	2.4	283
258	Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone Marrow Transplantation, 2015, 50, 759-769.	2.4	34

#	Article	IF	Citations
259	Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update. Bone Marrow Transplantation, 2015, 50, S24-S30.	2.4	35
260	T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells. Bone Marrow Transplantation, 2015, 50, S43-S50.	2.4	18
261	Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 1129-1131.	1.3	1
262	A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going!. Transfusion and Apheresis Science, 2015, 52, 360-368.	1.0	19
263	Haploidentical HSCT: a 15-year experience at San Raffaele. Bone Marrow Transplantation, 2015, 50, S67-S71.	2.4	6
264	Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Annals of Hematology, 2015, 94, 1677-1688.	1.8	60
265	An overview of conditioning regimens for haploidentical stem cell transplantation with postâ€transplantation cyclophosphamide. American Journal of Hematology, 2015, 90, 541-548.	4.1	31
266	Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 889-893.	2.0	106
267	Total Body Irradiationâ€“Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 1299-1307.	2.0	136
268	Engineering haploidentical transplants. Bone Marrow Transplantation, 2015, 50, 884-885.	2.4	0
269	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biology of Blood and Marrow Transplantation, 2015, 21, 1506-1514.	2.0	121
270	Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide. Medicine (United States), 2015, 94, e1200.	1.0	1
271	Allogreffe haploidentique en oncologie et hÃ©matologie pÃ©diatrique. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2015, 3, 206-214.	0.1	0
273	Current Challenges in Stem Cell Transplantation in Myelofibrosis. Current Hematologic Malignancy Reports, 2015, 10, 344-350.	2.3	13
274	Making strides and meeting challenges in pediatric allogeneic hematopoietic cell transplantation clinical trials in the United States: Past, present and future. Contemporary Clinical Trials, 2015, 45, 84-92.	1.8	12
275	Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis. Hematology, 2015, 20, 313-319.	1.5	2
276	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia, 2015, 29, 396-405.	7.2	114
277	Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigenâ€“Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 941-944.	2.0	48

#	Article	IF	Citations
278	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 906-912.	2.0	35
280	Transplant for MDS: Challenges and emerging strategies. Best Practice and Research in Clinical Haematology, 2015, 28, 43-54.	1.7	5
281	High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplantation, 2015, 50, 499-504.	2.4	9
282	Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplantation, 2015, 50, 476-482.	2.4	173
283	A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia, 2015, 29, 1069-1075.	7.2	57
284	Feasible Outcomes of T Cellâ€“Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 342-349.	2.0	23
285	Donor HLA-specific Abs: to BMT or not to BMT?. Bone Marrow Transplantation, 2015, 50, 751-758.	2.4	60
286	Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplantation, 2015, 50, 679-684.	2.4	21
287	Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies. Bone Marrow Transplantation, 2015, 50, 968-977.	2.4	72
288	Infections after Tâ€replete haploidentical transplantation and highâ€dose cyclophosphamide as graftâ€versusâ€host disease prophylaxis. Transplant Infectious Disease, 2015, 17, 242-249.	1.7	118
289	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood and Marrow Transplantation, 2015, 21, 2115-2122.	2.0	26
290	Effect of Graft Source on Unrelated Donor Hemopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia after Reduced-Intensity or Nonmyeloablative Conditioning: A Study from the SociÃ©tÃ© Francaise de Greffe de Moelle et de ThÃ©rapie Cellulaire. Biology of Blood and Marrow Transplantation, 2015, 21, 1059-1067.	2.0	24
291	Wanted: Prospective Studies of Alternative Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 957-958.	2.0	0
292	Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?. Current Hematologic Malignancy Reports, 2015, 10, 329-333.	2.3	3
293	Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants UsingÂHaploidentical Related Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 1641-1645.	2.0	38
294	Exercising â€˜vetoâ€™ power to make haploidentical hematopoietic stem cell transplantation a safe modality for induction of immune tolerance. Regenerative Medicine, 2015, 10, 239-242.	1.7	4
296	Haploidentical Hematopoietic Stem Cell Transplantation asÂaÂPlatform for Post-Transplantation Cellular Therapy. Biology of Blood and Marrow Transplantation, 2015, 21, 1714-1720.	2.0	30
297	HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplantation, 2015, 50, S31-S36.	2.4	71

#	Article	IF	Citations
298	Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplantation, 2015, 50, S37-S39.	2.4	142
299	Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 232-242.	3.4	20
300	HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2015, 21, 1646-1652.	2.0	88
301	A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 646-652.	2.0	41
302	Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2015, 50, 1001-1003.	2.4	9
303	Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes. Biology of Blood and Marrow Transplantation, 2015, 21, 1237-1245.	2.0	28
304	Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood, 2015, 125, 4103-4113.	1.4	188
305	The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs. Regenerative Medicine, 2015, 10, 331-343.	1.7	7
306	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood, 2015, 125, 2855-2864.	1.4	132
307	Blood and Marrow Transplant Handbook. , 2015, , .		11
308	Immune Reconstitution/Immunocompetence in Recipients of Kidney Plus Hematopoietic Stem/Facilitating Cell Transplants. Transplantation, 2015, 99, 288-298.	1.0	122
309	Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. Cancer, 2015, 121, 1809-1816.	4.1	31
310	Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplantation, 2015, 50, 619-627.	2.4	15
311	Alternative Donor Transplantationâ€"â€œMixing and Matchingâ€• the Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?. Current Hematologic Malignancy Reports, 2015, 10, 1-7.	2.3	10
312	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectivesâ€"a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2015, 50, 781-789.	2.4	294
313	Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S43-S49.	0.4	5
314	Haploidentical Bone Marrow Transplantation in 2015 and Beyond. Current Oncology Reports, 2015, 17, 57.	4.0	10
315	Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2015, 94, 1707-1715.	1.8	10

#	Article	IF	Citations
316	Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available. Bone Marrow Transplantation, 2015, 50, 865-867.	2.4	10
317	Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation. International Journal of Hematologic Oncology, 2015, 4, 113-126.	1.6	13
318	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. Journal of Clinical Oncology, 2015, 33, 3152-3161.	1.6	215
319	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 2015, 29, 2126-2133.	7.2	242
320	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology and Oncology, 2015, 8, 84.	17.0	160
321	HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome. Experimental Hematology, 2015, 43, 921-929.e1.	0.4	32
322	B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY. Bone Marrow Transplantation, 2015, 50, 317-319.	2.4	14
323	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. International Journal of Hematology, 2015, 101, 243-254.	1.6	21
324	â€œNo donorâ€? Consider a haploidentical transplant. Blood Reviews, 2015, 29, 63-70.	5.7	42
325	High Fever Occurring 4 to 5 Days Post-Transplant of Haploidentical Bone Marrow or Peripheral Blood Stem Cells after Reduced-Intensity Conditioning Associated with the UseÂof Post-Transplant Cyclophosphamide as Prophylaxis for Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 197-198.	2.0	40
326	Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biology of Blood and Marrow Transplantation, 2015, 21, 4-7.	2.0	83
327	Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplantation, 2015, 50, 127-133.	2.4	42
328	Haploidentical hematopoietic SCT for acquired severe aplastic anemia using post-transplant high-dose CY. Bone Marrow Transplantation, 2015, 50, 155-156.	2.4	11
329	Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 604-611.	2.0	108
330	A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 119-129.	2.0	36
331	IMMUNITY TO INFECTIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016057.	1.3	15
332	THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, e2016045.	1.3	4
333	Haploidentical transplantation of hematopoietic stem cells. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2016, 62, 29-33.	0.7	1

#	Article	IF	Citations
334	Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues. Advances in Hematology, 2016, 2016, 1-11.	1.0	10
335	Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide. Advances in Hematology, 2016, 2016, 1-7.	1.0	28
336	Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies. Advances in Hematology, 2016, 2016, 1-16.	1.0	16
337	Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrowâ€"Review of Published Literature. Advances in Hematology, 2016, 2016, 1-11.	1.0	9
338	Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies. Advances in Hematology, 2016, 2016, 1-8.	1.0	32
339	Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance. Advances in Hematology, 2016, 2016, 1-8.	1.0	33
340	HLA-haploidentical stem cell transplantation -current trends and issues-. Journal of Hematopoietic Cell Transplantation, 2016, 5, 64-73.	0.1	0
341	Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders. Advances in Hematology, 2016, 2016, 1-8.	1.0	10
342	Milestones of Hematopoietic Stem Cell Transplantation â€“ From First Human Studies to Current Developments. Frontiers in Immunology, 2016, 7, 470.	4.8	82
343	Haploidentical stem cell transplant: Established treatment, expanding horizons. Asian Journal of Oncology, 0, 02, 008-013.	0.2	2
344	Haploidentical Transplantation Without In Vitro T-Cell Depletion Results in Outcomes Equivalent to Those of Contemporaneous Matched Sibling and Unrelated Donor Transplantation for Acute Leukemia. Medicine (United States), 2016, 95, e2973.	1.0	30
345	Outcomes of pediatric identical livingâ€donor liver and hematopoietic stem cell transplantation. Pediatric Transplantation, 2016, 20, 888-897.	1.0	15
346	Postâ€transplantation cyclophosphamide versus conventional graftâ€versusâ€host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. British Journal of Haematology, 2016, 173, 444-455.	2.5	61
347	Persistent Multiyear Control of Relapsed Tâ€Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report. Pediatric Blood and Cancer, 2016, 63, 1279-1282.	1.5	5
348	Postâ€transplant bendamustine reduces Gv<scp>HD</scp> while preserving GvL in experimental haploidentical bone marrow transplantation. British Journal of Haematology, 2016, 174, 102-116.	2.5	27
349	Inhibitory killer cell immunoglobulinâ€like receptor (<scp>iKIR</scp>) mismatches improve survival after Tâ€cellâ€repleted haploidentical transplantation. European Journal of Haematology, 2016, 96, 483-491.	2.2	15
350	T Cellâ€"Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1861-1866.	2.0	12
351	The evolution of Tâ€cell depletion in haploidentical stemâ€cell transplantation. British Journal of Haematology, 2016, 172, 667-684.	2.5	49

#	Article	IF	Citations
352	Desensitization with plasma exchange in a patient with human leukocyte antigen donorâ€specific antibodies before Tâ€cellâ€“replete haploidentical transplantation. Transfusion, 2016, 56, 1096-1100.	1.6	11
354	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50Âyearsâ€"a report from the EBMT acute leukemia working party. Journal of Hematology and Oncology, 2016, 9, 65.	17.0	17
355	Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation. Blood, 2016, 128, 2616-2623.	1.4	54
357	Hematopoietic Stem Cell Transplantation in Children and Adolescents. Pediatrics in Review, 2016, 37, 135-145.	0.4	15
358	Comparison of Outcomes of Hematopoietic Cell TransplantsÂfrom T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A,Â-B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. Biology of Blood and Marrow Transplantation, 2016, 22, 125-133.	2.0	135
359	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplantation, 2016, 51, 1307-1312.	2.4	31
360	Nonmyeloablative allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, 521-530.	3.5	46
361	Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfusion and Apheresis Science, 2016, 54, 345-355.	1.0	54
362	Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. Leukemia, 2016, 30, 2102-2106.	7.2	43
363	Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation. Bone Marrow Transplantation, 2016, 51, 949-954.	2.4	20
364	The devil is in the T cells: relapsing after haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2016, 51, 915-918.	2.4	3
365	Advances in haploidentical stem cell transplantation for hematologic malignancies. Leukemia and Lymphoma, 2016, 57, 1766-1775.	1.3	13
366	Factors Predicting Graft-versus-Host Diseaseâ€"Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. Biology of Blood and Marrow Transplantation, 2016, 22, 1403-1409.	2.0	41
367	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia, 2016, 30, 2086-2089.	7.2	45
368	Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 2016, 25, 957-972.	4.1	22
369	Cell Manipulation in Pediatric Haploidentical Stem Cell Transplantation: State of the Art. Journal of Pediatric Biochemistry, 2016, 05, 115-119.	0.2	0
370	HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 1275-1278.	2.4	3
371	Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood, 2016, 127, 62-70.	1.4	237

#	Article	IF	Citations
372	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood, 2016, 127, 1502-1508.	1.4	174
373	Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants. Blood, 2016, 127, 1539-1543.	1.4	32
374	Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone Marrow Transplantation, 2016, 51, 1602-1604.	2.4	12
375	Comparison of Donor Sources in Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Nationwide Retrospective Study. Biology of Blood and Marrow Transplantation, 2016, 22, 2226-2234.	2.0	15
376	Haploidentical related donor hematopoietic stem cell transplantation withÂpost-transplantation cyclophosphamide for DOCK8 deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1239-1242.e1.	3.8	16
377	Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. Bone Marrow Transplantation, 2016, 51, 1620-1621.	2.4	17
378	Human Herpesvirus 6 replication predicts Cytomegalovirus reactivation after allogeneic stem cell transplantation from haploidentical donor. Journal of Clinical Virology, 2016, 84, 24-26.	3.1	20
379	Cytomegalovirus Infection After Stem Cell Transplantation. , 2016, , 417-440.		3
380	Risks and Epidemiology of Infections After Hematopoietic Stem Cell Transplantation. , 2016, , 81-99.		9
381	Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia. International Journal of Hematology, 2016, 104, 720-728.	1.6	11
385	Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes. Biology of Blood and Marrow Transplantation, 2016, 22, 2031-2037.	2.0	5
386	Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation. Journal of Experimental Medicine, 2016, 213, 1865-1880.	8.5	6
387	Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation. Journal of Clinical Virology, 2016, 82, 33-40.	3.1	27
388	The patientâ€™s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplantation, 2016, 51, 1134-1136.	2.4	23
389	Gv<scp>HD</scp> prophylaxis in nonâ€haploidentical allogeneic peripheral blood stem cell transplantation: beyond the standard to prevent relapse in patients with highâ€risk chronic lymphoproliferative diseases?. European Journal of Haematology, 2016, 96, 7-8.	2.2	0
390	Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplantation, 2016, 51, 1599-1601.	2.4	39
391	Haploidentical transplants using ex vivo T-cell depletion. Seminars in Hematology, 2016, 53, 252-256.	3.4	17
392	Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia. Molecular Therapy, 2016, 24, 1655-1664.	8.2	8

#	Article	IF	Citations
393	Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 2047-2055.	2.0	45
394	Total Body Irradiation. , 2016, , 341-357.e7.		1
395	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood, 2016, 128, 1528-1531.	1.4	46
396	Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigenâ€“Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 2065-2076.	2.0	31
397	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood, 2016, 127, 352-359.	1.4	29
398	Concise Review: Recent Advances in the In Vitro Derivation of Blood Cell Populations. Stem Cells Translational Medicine, 2016, 5, 1330-1337.	3.3	19
399	Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies. Pediatric Blood and Cancer, 2016, 63, 2033-2037.	1.5	17
400	Haploidentical versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia: Should Donor Type Matter Anymore?. Biology of Blood and Marrow Transplantation, 2016, 22, 1540-1542.	2.0	1
401	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer, 2016, 122, 3316-3326.	4.1	75
402	Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview. Cancer Research, 2016, 76, 6445-6451.	0.9	161
403	Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 1644-1646.	2.4	4
404	Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. OncoImmunology, 2016, 5, e1242546.	4.6	11
405	Current status and future perspective of hematopoietic stem cell transplantation. Major Histocompatibility Complex, 2016, 23, 108-114.	0.1	0
406	Bone marrow chimerism as a strategy to produce tolerance in solid organ allotransplantation. Current Opinion in Organ Transplantation, 2016, 21, 595-602.	1.6	2
407	High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. Journal of Pediatric Hematology/Oncology, 2016, 38, 627-635.	0.6	11
409	Bone marrow donorâ€related variables associated with harvest outcome in <scp>HLA</scp>â€haploidentical transplantation with postinfusion cyclophosphamide. Vox Sanguinis, 2016, 111, 93-100.	1.5	3
410	Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center. Bone Marrow Transplantation, 2016, 51, 1354-1360.	2.4	24
411	How to select the best available related or unrelated donor of hematopoietic stem cells?. Haematologica, 2016, 101, 680-687.	3.5	150

#	Article	IF	Citations
412	Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update. Bone Marrow Transplantation, 2016, 51, 1464-1469.	2.4	15
413	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. Journal of Hematology and Oncology, 2016, 9, 25.	17.0	57
414	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. Journal of Hematology and Oncology, 2016, 9, 35.	17.0	78
415	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. Journal of Clinical Oncology, 2016, 34, 3141-3149.	1.6	212
416	Haploidentical hematopoietic stem cell transplantation with postâ€transplant highâ€dose cyclophosphamide in highâ€risk children: A singleâ€center study. Pediatric Transplantation, 2016, 20, 417-423.	1.0	8
417	Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond postâ€transplantation cyclophosphamide in younger children. Pediatric Transplantation, 2016, 20, 675-682.	1.0	26
418	Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation, 2016, 22, 1851-1860.	2.0	135
419	Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Hematological Oncology, 2016, 34, 154-160.	1.7	6
420	<scp>OCTET</scp>â€<scp>CY</scp>: a phase <scp>II</scp> study to investigate the efficacy of postâ€transplant cyclophosphamide as sole graftâ€versusâ€host prophylaxis after allogeneic peripheral blood stem cell transplantation. European Journal of Haematology, 2016, 96, 27-35.	2.2	52
421	Haploidentical transplantation: selecting optimal conditioning regimen and stem cell source. Seminars in Hematology, 2016, 53, 111-114.	3.4	16
422	Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 499-504.	2.0	60
423	Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. Bone Marrow Transplantation, 2016, 51, 462-465.	2.4	6
424	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy, 2016, 8, 435-447.	2.0	28
425	Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives. Blood Reviews, 2016, 30, 297-307.	5.7	23
426	Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Seminars in Hematology, 2016, 53, 98-102.	3.4	17
427	Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future. Expert Review of Clinical Immunology, 2016, 12, 713-723.	3.0	11
428	Alternative donor allogeneic hematopoietic cell transplantation for hemoglobinopathies. Seminars in Hematology, 2016, 53, 120-128.	3.4	14
429	Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study. Biology of Blood and Marrow Transplantation, 2016, 22, 902-909.	2.0	69

#	Article	IF	Citations
430	Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. Biology of Blood and Marrow Transplantation, 2016, 22, 895-901.	2.0	64
431	Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. Biology of Blood and Marrow Transplantation, 2016, 22, 324-329.	2.0	56
432	Unmanipulated haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with paroxysmal nocturnal hemoglobinuria and secondary aplastic anemia. Bone Marrow Transplantation, 2016, 51, 316-318.	2.4	4
433	Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology. International Journal of Hematology, 2016, 103, 380-386.	1.6	9
434	Hematopoietic stem cell transplantation in Europe 2014: more than 40â€‰000 transplants annually. Bone Marrow Transplantation, 2016, 51, 786-792.	2.4	338
435	Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Seminars in Hematology, 2016, 53, 90-97.	3.4	118
436	T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplantation, 2016, 51, 194-198.	2.4	22
437	Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 391-397.	2.4	54
438	Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. Expert Opinion on Biological Therapy, 2016, 16, 347-364.	3.1	4
439	A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 141-148.	2.0	29
440	Haploidentical T Cellâ€“Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigenâ€“Matched Related or Unrelated Donor. Biology of Blood and Marrow Transplantation, 2016, 22, 119-124.	2.0	86
441	Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplantation, 2016, 51, 205-211.	2.4	52
442	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leukemia and Lymphoma, 2016, 57, 666-675.	1.3	11
443	Success of haploidentical hematopoietic stem cells transplantation in the treatment of graft failure. Annals of Hematology, 2016, 95, 353-354.	1.8	2
444	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigenâ€“Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 112-118.	2.0	37
445	Modern approaches to HLA-haploidentical blood or marrow transplantation. Nature Reviews Clinical Oncology, 2016, 13, 10-24.	27.6	262
446	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. Leukemia, 2016, 30, 447-455.	7.2	85
447	Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation. Journal of Oncology Pharmacy Practice, 2016, 22, 275-283.	0.9	3

#	Article	IF	Citations
448	Human Leukocyte Antigenâ€“Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis. Biology of Blood and Marrow Transplantation, 2017, 23, 705-707.	2.0	7
449	Clinical Studies of Ex Vivo Expansion to Accelerate Engraftment After Umbilical Cord Blood Transplantation: A Systematic Review. Transfusion Medicine Reviews, 2017, 31, 173-182.	2.0	42
450	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2017, 23, 612-617.	2.0	17
451	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. Biology of Blood and Marrow Transplantation, 2017, 23, 677-683.	2.0	12
452	Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia. Bone Marrow Transplantation, 2017, 52, 570-573.	2.4	13
453	Successful haploidentical BMT with post-transplant cyclophosphamide for refractory autoimmune pancytopenia after cord blood transplant in pediatric myelodysplastic syndrome. Bone Marrow Transplantation, 2017, 52, 653-655.	2.4	0
454	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 2017, 52, 689-696.	2.4	31
455	T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 648-653.	2.0	38
456	Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplantation, 2017, 52, 683-688.	2.4	42
457	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica, 2017, 102, 391-400.	3.5	152
458	A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. Journal of Hematology and Oncology, 2017, 10, 24.	17.0	70
459	Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 898-901.	2.4	13
460	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 769-771.	2.4	3
461	Late effects of blood and marrow transplantation. Haematologica, 2017, 102, 614-625.	3.5	126
462	Allogeneic transplantation using <scp>CD</scp>34⁺ selected peripheral blood progenitor cells combined with nonâ€•mobilized donor TÂcells for refractory severe aplastic anaemia. British Journal of Haematology, 2017, 176, 950-960.	2.5	7
463	Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation, 2017, 52, 634-637.	2.4	1
464	Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. Haematologica, 2017, 102, 932-940.	3.5	27
465	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2

#	Article	IF	Citations
466	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. Expert Review of Hematology, 2017, 10, 479-492.	2.2	34
467	Allogeneic Stem Cell Transplantation in Myelofibrosis. Biology of Blood and Marrow Transplantation, 2017, 23, 1429-1436.	2.0	29
468	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2017, 23, 1549-1554.	2.0	25
469	Relapsed Acute Lymphoblastic Leukemia of Childhood. , 2017, , 255-297.		1
470	Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. Expert Review of Hematology, 2017, 10, 433-448.	2.2	30
471	HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG:) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.5	12
472	Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. Breast Cancer Research and Treatment, 2017, 161, 421-433.	2.5	1
474	Hematopoietic cell transplantation: Training challenges and potential opportunities through networking and integration of modern technologies to the practice setting. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 184-188.	0.9	4
475	ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers. Chemico-Biological Interactions, 2017, 276, 46-51.	4.0	31
476	Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplantation, 2017, 52, 1253-1260.	2.4	23
477	Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 1047-1048.	2.4	7
478	Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Bone Marrow Transplantation, 2017, 52, 1208-1211.	2.4	8
479	Recovery from Cyclophosphamide Overdose in a Dog. Journal of the American Animal Hospital Association, 2017, 53, 230-235.	1.1	6
480	Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biology of Blood and Marrow Transplantation, 2017, 23, 1555-1566.	2.0	21
481	Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. Bone Marrow Transplantation, 2017, 52, 1273-1279.	2.4	11
482	Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 79-84.	0.9	14
483	Hematopoietic stem cell transplantation and cellular therapy. Hla, 2017, 89, 267-277.	0.6	21
484	Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis. Annals of Hematology, 2017, 96, 935-942.	1.8	2

#	Article	IF	Citations
485	Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. Bone Marrow Transplantation, 2017, 52, 1138-1143.	2.4	20
486	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2017, 52, 811-817.	2.4	310
488	Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2017, 23, 980-990.	2.0	39
489	Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. Bone Marrow Transplantation, 2017, 52, 1241-1248.	2.4	64
490	Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation. Leukemia Research, 2017, 57, 27-36.	0.8	15
491	Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplant. Haematologica, 2017, 102, 401-410.	3.5	109
492	Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 498-504.	2.0	93
493	A Canine Model of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 420-427.	2.0	14
494	Classification systems for chronic graft-versus-host disease. Blood, 2017, 129, 30-37.	1.4	218
495	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplantation, 2017, 52, 620-621.	2.4	23
496	Spousal hematopoietic stem cell transplantation. International Journal of Hematology, 2017, 105, 646-657.	1.6	2
497	Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant. Future Oncology, 2017, 13, 935-944.	2.4	3
498	Donorâ€derived <scp>CD</scp>19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2017, 179, 598-605.	2.5	87
499	Outcome of Haploidentical SCT in Patients with Acute Leukemia. Pancreatic Islet Biology, 2017, , 103-117.	0.3	0
500	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. OncoImmunology, 2017, 6, e1356152.	4.6	28
501	Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation. Oncology Research and Treatment, 2017, 40, 691-696.	1.2	5
502	Steroid treatment of acute graft- versus -host disease grade I: a randomized trial. Haematologica, 2017, 102, 2125-2133.	3.5	27
503	T Cellâ€“Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model. Biology of Blood and Marrow Transplantation, 2017, 23, 2048-2056.	2.0	4

#	Article	IF	Citations
504	Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 2137-2142.	2.0	14
505	Successful Reduced Intensity Conditioning Alternate Donor Stem Cell Transplant for Wiskott-Aldrich Syndrome. Journal of Pediatric Hematology/Oncology, 2017, 39, e493-e496.	0.6	10
506	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 1810-1822.	3.5	64
507	Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies. Blood Cells, Molecules, and Diseases, 2017, 67, 155-168.	1.4	11
508	Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. Biology of Blood and Marrow Transplantation, 2017, 23, 2192-2198.	2.0	21
509	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 1903-1909.	2.0	14
510	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 2088-2095.	2.0	9
511	Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1887-1894.	2.0	42
512	The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60 years. Blood Reviews, 2017, 31, 362-369.	5.7	20
513	Sometimes less might be more, or at least equal. Blood, 2017, 130, 565-566.	1.4	7
514	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 2127-2136.	2.0	17
515	Physicians â€“ Poster Session. Bone Marrow Transplantation, 2017, 52, S124-S516.	2.4	2
516	Genomics trumps clinical criteria in BMT? Nyet!. Blood, 2017, 129, 2335-2336.	1.4	0
518	Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies. Clinics in Chest Medicine, 2017, 38, 575-593.	2.1	11
519	Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature. Experimental Hematology and Oncology, 2017, 6, 24.	5.0	8
520	Alternative Donor/Unrelated Donor Transplants for the Î²-Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology, 2017, 1013, 123-153.	1.6	10
521	Future Perspectives for Haploidentical SCT. Pancreatic Islet Biology, 2017, , 189-199.	0.3	1
522	Haploidentical Stem Cell Transplantation. Pancreatic Islet Biology, 2017, , .	0.3	1

#	Article	IF	Citations
523	Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 959-966.	4.9	6
524	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 1736-1743.	2.0	44
525	HLA-mismatched bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplantation, 2017, 52, 1347-1348.	2.4	3
526	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transplant Infectious Disease, 2017, 19, e12629.	1.7	75
527	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 310-317.	2.0	50
528	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 318-324.	2.0	54
529	Prior history of HLA-mismatched stem cell transplantation is a risk factor for graft failure in HLA-haploidentical transplantation. Bone Marrow Transplantation, 2017, 52, 323-325.	2.4	0
530	Low incidence of chronic <scp>GVHD</scp> after <scp>HLA</scp>â€haploidentical peripheral blood stem cell transplantation with postâ€transplantation cyclophosphamide in older patients. British Journal of Haematology, 2017, 176, 132-135.	2.5	17
531	Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. Bone Marrow Transplantation, 2017, 52, 147-150.	2.4	5
532	Halfway there: the past, present and future of haploidentical transplantation. Bone Marrow Transplantation, 2017, 52, 1-6.	2.4	26
533	The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation, 2017, 52, 135-137.	2.4	12
534	Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure. Bone Marrow Transplantation, 2017, 52, 157-158.	2.4	4
535	Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia. European Journal of Haematology, 2017, 98, 177-183.	2.2	3
536	Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation. Lupus, 2017, 26, 773-776.	1.6	7
537	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 325-332.	2.0	61
538	Hematopoietic cell transplants for BCR/ABL negative acute lymphocytic leukemia. , 0, , 298-308.		0
539	ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. Blood Advances, 2017, 1, 573-576.	5.2	27
540	Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint. Blood Advances, 2017, 1, 401-406.	5.2	17

#	Article	IF	Citations
541	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Advances, 2017, 1, 288-292.	5.2	84
542	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Advances, 2017, 1, 652-661.	5.2	84
543	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Advances, 2017, 1, 669-680.	5.2	43
544	Haploidentical Transplantation. , 2017, , 121-125.		0
545	T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation. Biomedicines, 2017, 5, 33.	3.2	33
546	Role of Î±Î² T Cell Depletion in Prevention of Graft versus Host Disease. Biomedicines, 2017, 5, 35.	3.2	32
547	Pathophysiology of GvHD and Other HSCT-Related Major Complications. Frontiers in Immunology, 2017, 8, 79.	4.8	166
548	Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation. Frontiers in Immunology, 2017, 8, 1762.	4.8	39
549	Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers. Current Drug Targets, 2017, 18, 281-295.	2.1	12
550	Intravital longitudinal wide-area imaging of dynamic bone marrow engraftment and multilineage differentiation through nuclear-cytoplasmic labeling. PLoS ONE, 2017, 12, e0187660.	2.5	17
551	Hematopoietic cell transplants for children with acute lymphoblastic leukemia. , 0, , 291-297.		0
553	Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure. Hematology Reports, 2017, 9, 7091.	0.8	0
554	Selecting the best donor for an allogeneic hematopoietic cell transplant. , 0, , 59-64.		0
555	Prevention of acute graft-versus-host disease â€“ one size fits all?. , 0, , 105-111.		0
556	Conditioning regimens: Do they really matter?. , 0, , 247-257.		0
557	T-cell depletion in allogeneic hematopoietic cell transplantation: Results, barriers, and future directions. , 0, , 271-282.		0
558	Human leukocyte antigen-haplotype mismatch transplants: Overcoming major genetic barriers. , 0, , 559-568.		0
559	Selecting human leukocyte antigen haplotype mismatch versus cord blood graft. , 0, , 579-590.		0

#	Article	IF	Citations
560	Biology: Critical components of hematopoietic cell transplantation. , 0, , 16-22.		0
561	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2017, 35, 3425-3432.	1.6	132
562	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cellâ€“Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2017, 35, 3002-3009.	1.6	255
563	Haploidentical Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide: Does Graft Source Matter?. Journal of Clinical Oncology, 2017, 35, 2984-2986.	1.6	8
564	Stem Cells in Kidney Transplantation: A Review of Chimerism-Based Protocols to Induce Transplantation Tolerance. Current Regenerative Medicine, 2017, 6, 16-23.	0.0	0
565	HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Biology of Blood and Marrow Transplantation, 2018, 24, 1449-1454.	2.0	39
566	Clinical-scale manufacturing of Î³Î´ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis. Bone Marrow Transplantation, 2018, 53, 766-769.	2.4	8
567	Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplantation, 2018, 53, 756-763.	2.4	35
568	Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Review of Hematology, 2018, 11, 273-284.	2.2	20
569	Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 368-374.	0.4	3
570	Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biology of Blood and Marrow Transplantation, 2018, 24, 1671-1677.	2.0	13
571	Haploidentical stem cell transplantation-bone marrow vs peripheral blood. Transfusion and Apheresis Science, 2018, 57, 168-170.	1.0	7
572	Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis. Journal of Pediatric Hematology/Oncology, 2018, 40, e350-e354.	0.6	2
573	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1759-1765.	2.0	50
574	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	2.4	10
575	Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. Leukemia Research, 2018, 69, 31-38.	0.8	5
576	Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform. Biology of Blood and Marrow Transplantation, 2018, 24, 1108-1110.	2.0	7
578	Hematopoietic stem cell transplantation for acute myeloid leukemia. International Journal of Hematology, 2018, 107, 513-518.	1.6	56

#	Article	IF	Citations
580	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1022-1028.	2.0	29
581	Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. Biology of Blood and Marrow Transplantation, 2018, 24, 1250-1259.	2.0	71
582	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1243-1249.	2.0	49
583	Single Antigenâ€“Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1196-1202.	2.0	50
585	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Nonâ€“First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102.	2.0	61
586	Riskâ€adapted <scp>GVHD</scp> prophylaxis with postâ€transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. European Journal of Haematology, 2018, 100, 395-402.	2.2	19
587	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer, 2018, 124, 1428-1437.	4.1	131
588	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplantation, 2018, 53, 255-263.	2.4	14
589	Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. Bone Marrow Transplantation, 2018, 53, 361-365.	2.4	28
590	Have haploidentical transplants replaced umbilical cord transplants for acute leukemias?. Current Opinion in Hematology, 2018, 25, 103-111.	2.5	18
591	Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1013-1021.	2.0	59
592	Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation. Bone Marrow Transplantation, 2018, 53, 392-399.	2.4	16
593	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplantation, 2018, 53, 422-430.	2.4	24
594	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biology of Blood and Marrow Transplantation, 2018, 24, 1274-1280.	2.0	46
595	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkinâ€™s lymphoma undergoing allogeneic haematopoietic cell transplantationâ€”a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation, 2018, 53, 400-409.	2.4	34
596	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2018, 53, 521-534.	2.4	168
597	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 600-608.	2.4	9
598	Historical Perspective and Current Trends in Haploidentical Transplantation. , 2018, , 1-11.		0

#	Article	IF	Citations
599	Haploidentical Transplants and NK Cell Alloreactivity. , 2018, , 145-157.		0
600	Myeloablative Versus Nonmyeloablative Conditioning Regimen in Haploidentical Transplantation: Does It Matter and How Best to Select Between the Two?. , 2018, , 159-171.		0
601	Haploidentical Transplants for Nonmalignant Diseases in Children. , 2018, , 175-194.		0
602	Haploidentical Hematopoietic Cell Transplantation in Children with Neoplastic Disorders. , 2018, , 195-215.		0
603	Haploidentical Transplants: Nonmalignant Diseases in Adults. , 2018, , 219-229.		0
604	Haploidentical Transplants for Acute Myeloid Leukemia in Adults. , 2018, , 231-243.		0
605	Haploidentical Hematopoietic Cell Transplantation in Lymphomas. , 2018, , 245-260.		0
606	Haploidentical Transplants: Immune Reconstitution With and Without Augmentation Strategies. , 2018, , 271-289.		0
607	Prevention and Treatment of Relapse After HLA-Haploidentical Hematopoietic Cell Transplantation. , 2018, , 291-306.		1
608	Unique Complications and Limitations of Haploidentical Hematopoietic Cell Transplant. , 2018, , 307-323.		0
609	Future Prospects: Haploidentical Transplantation. , 2018, , 325-337.		0
610	Adoptive Immunotherapy with Regulatory and Conventional T-cells in Haploidentical T-cell Depleted Transplantation Protects from GvHD and Exerts GvL Effect. , 2018, , 43-54.		0
611	Post-transplant Cyclophosphamide in Haploidentical Transplantation. , 2018, , 89-107.		0
612	Graft Source: Marrow or Peripheral Blood with Posttransplant Cyclophosphamideâ€"What Matters?. , 2018, , 111-125.		0
613	Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. Journal of Hematology and Oncology, 2018, 11, 40.	17.0	130
614	Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility. Bone Marrow Transplantation, 2018, 53, 1390-1400.	2.4	5
615	Toward Safer CD34+ Megadose T-Cell-Depleted Transplants Following Reduced Intensity and Nonmyeloablative Conditioning Regimens. , 2018, , 15-28.		0
616	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplantation, 2018, 53, 1522-1531.	2.4	22

#	Article	IF	Citations
617	The early expansion of anergic NKG2A^{pos}/CD56^{dim}/CD16^{neg} natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. Haematologica, 2018, 103, 1390-1402.	3.5	61
618	Haploidentical stem cell transplantation: T cell depleted and repleted. Transfusion and Apheresis Science, 2018, 57, 171-173.	1.0	2
619	Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. American Journal of Hematology, 2018, 93, 769-777.	4.1	22
620	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clinical Cancer Research, 2018, 24, 2794-2803.	7.0	32
621	The current and future role of stem cells in myelodysplastic syndrome therapies. Expert Review of Hematology, 2018, 11, 411-422.	2.2	9
622	Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell Infusion: The importance of durable chimerism. Human Immunology, 2018, 79, 272-276.	2.4	47
623	Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 96-98.	0.9	5
624	Investigating covariate-by-centre interaction in survival data. Statistical Methods in Medical Research, 2018, 27, 920-932.	1.5	6
625	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 343-352.	2.0	61
626	Donor lymphocyte infusion and methotrexate for immune recovery after Tâ€cell depleted haploidentical transplantation. American Journal of Hematology, 2018, 93, 169-178.	4.1	9
627	Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 413-417.	2.0	8
628	Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 353-358.	2.0	43
629	Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 119-126.	2.0	37
630	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 78-85.	2.0	9
631	From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders. , 2018, 176, 784-803.		12
632	Reducedâ€toxicity alternateâ€donor stem cell transplantation with posttransplant cyclophosphamide for primary immunodeficiency disorders. Pediatric Blood and Cancer, 2018, 65, e26783.	1.5	27
633	Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation. Leukemia and Lymphoma, 2018, 59, 2005-2007.	1.3	4
634	Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. Human Immunology, 2018, 79, 258-265.	2.4	40

#	Article	IF	Citations
635	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
636	Killer Cell Immunoglobulin-Like Receptorâ€“Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cellâ€“Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 549-554.	2.0	35
637	Allogeneic Stem Cell Transplantation. , 2018, , 39-64.		1
638	Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 494-500.	2.0	22
639	Cyclophosphamideâ€induced tolerance in kidney transplantation avoids longâ€term immunosuppressive therapy. International Journal of Urology, 2018, 25, 112-120.	1.0	7
640	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. International Journal of Hematology, 2018, 107, 478-485.	1.6	11
641	T-cell-replete haploidentical transplantation in acute myeloid leukemia. Experimental Hematology, 2018, 58, 5-16.	0.4	7
642	Review of Haploidentical Hematopoietic Cell Transplantation. Journal of Global Oncology, 2018, 4, 1-13.	0.5	10
644	THE FUTURE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION. Japanese Journal of Transfusion and Cell Therapy, 2018, 64, 675-680.	0.2	0
645	Facilitating cells: role in inducing transplantation tolerance. Current Opinion in Organ Transplantation, 2018, 23, 546-551.	1.6	1
646	Facilitating Cells: A Journey from Bench to Bedside. Journal of Clinical & Cellular Immunology, 2018, 09, .	1.5	0
648	Transplantation of Hematopoietic Stem Cells for Primary Immunodeficiencies in Brazil: Challenges in Treating Rare Diseases in Developing Countries. Journal of Clinical Immunology, 2018, 38, 917-926.	3.8	13
649	Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Advances, 2018, 2, 2226-2229.	5.2	47
650	Can haploidentical transplantation meet all patients' needs?. Best Practice and Research in Clinical Haematology, 2018, 31, 410-413.	1.7	4
651	Haploidentical peripheral blood stem cell transplantation using T cell replete grafts with post-transplant high dose cyclophosphamide: Report of two cases. Current Medicine Research and Practice, 2018, 8, 144-146.	0.1	1
652	Should an HLA-matched donor still be considered the perfect donor?. Lancet Haematology,the, 2018, 5, e388-e390.	4.6	4
653	Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation. Nature Communications, 2018, 9, 4438.	12.8	18
654	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults. , 2018, , 970-980.e4.		0

#	Article	IF	Citations
655	Haploidentical Stem Cell Transplantation. , 2018, , 291-305.		0
656	Evaluation of Ca²⁺ Binding Sites in Tacrolimus by Infrared Multiple Photon Dissociation Spectroscopy. Journal of Physical Chemistry B, 2018, 122, 9860-9868.	2.6	6
657	Sequential HLAâ€haploidentical transplantation utilizing postâ€transplantation cyclophosphamide for GvHD prophylaxis in highâ€risk and relapsed/refractory AML/MDS. American Journal of Hematology, 2018, 93, 1524-1531.	4.1	17
658	Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRÎ±Î²+/CD19+-depleted grafts. Blood Advances, 2018, 2, 263-270.	5.2	76
659	Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. Blood Advances, 2018, 2, 575-585.	5.2	7
660	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Advances, 2018, 2, 299-307.	5.2	69
661	HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. Blood Advances, 2018, 2, 3590-3601.	5.2	16
662	Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clinical Cancer Research, 2018, 24, 4098-4109.	7.0	9
663	Loss of Mismatched HLA in Acute Leukemia Pediatric Patients after a Haploidentical Hematopoietic Stem Cell Transplantation. Major Histocompatibility Complex, 2018, 25, 34-39.	0.1	0
664	Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. Bone Marrow Transplantation, 2018, 53, 1560-1567.	2.4	5
665	Busulfanâ€based myeloablative conditioning regimens for haploidentical transplantation in highâ€risk acute leukemias and myelodysplastic syndromes. European Journal of Haematology, 2018, 101, 332-339.	2.2	11
666	Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia. Hematology/Oncology Clinics of North America, 2018, 32, 629-642.	2.2	18
667	When there is no match, the game is not over: Alternative donor options for hematopoietic stem cell transplantation in sickle cell disease. Seminars in Hematology, 2018, 55, 94-101.	3.4	15
668	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2047-2055.	2.0	18
669	Runaway Train: A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas. Case Reports in Immunology, 2018, 2018, 1-6.	0.4	6
670	Haploidentical Hematopoietic Cell Transplantation. , 2018, , 1617-1632.e6.		0
671	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, 2259-2264.	2.0	66
672	Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment. Biology of Blood and Marrow Transplantation, 2018, 24, e26-e30.	2.0	16

#	Article	IF	Citations
673	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. American Journal of Hematology, 2018, 93, 1236-1244.	4.1	40
674	Chimerism: A Clinical Guide to Tolerance Induction. , 2018, , 135-152.		0
675	Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an <scp>FBCA</scp> conditioning regimen. British Journal of Haematology, 2018, 182, 554-558.	2.5	15
676	HLA in transplantation. Nature Reviews Nephrology, 2018, 14, 558-570.	9.6	114
677	Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients. Annals of Hematology, 2018, 97, 2205-2215.	1.8	4
678	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2018, 103, 1317-1328.	3.5	84
679	Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskottâ€“Aldrich syndrome. Pediatric Blood and Cancer, 2018, 65, e27092.	1.5	12
681	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. Bone Marrow Transplantation, 2018, 53, 1345-1348.	2.4	4
682	Rescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a singleâ€centre case series. Internal Medicine Journal, 2018, 48, 988-991.	0.8	5
683	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 2056-2064.	2.0	32
684	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, 2034-2039.	2.0	32
685	Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: A meta-analysis. PLoS ONE, 2018, 13, e0191955.	2.5	10
686	Chimerism. , 2018, , .		0
687	Gastrointestinal Graft-versus-Host Disease Is a Risk Factor for Postengraftment Bloodstream Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2018, 24, 2302-2309.	2.0	25
688	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia, 2019, 33, 230-239.	7.2	36
689	Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplantation, 2019, 54, 432-441.	2.4	69
690	Who is the best donor for haploidentical stem cell transplantation?. Seminars in Hematology, 2019, 56, 194-200.	3.4	15
691	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Annals of Hematology, 2019, 98, 2389-2398.	1.8	24

#	Article	IF	Citations
692	Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 2422-2430.	2.0	37
693	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2431-2437.	2.0	54
694	Post-transplantation cyclophosphamide for chimerism-based tolerance. Bone Marrow Transplantation, 2019, 54, 769-774.	2.4	15
695	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. Journal of Hematology and Oncology, 2019, 12, 68.	17.0	22
696	Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis. Japanese Journal of Clinical Oncology, 2019, 49, 924-931.	1.3	10
697	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Frontiers in Immunology, 2019, 10, 1570.	4.8	48
698	History and Current Status of Hematopoietic Cell Transplantation. , 2019, , 1-18.		0
699	T-Cell Replete Haploidentical Transplantation. , 2019, , 99-123.		1
700	Haploidentical stem cell transplantation with posttransplant cyclophosphamide for refractory systemic juvenile xanthogranuloma. Pediatric Blood and Cancer, 2019, 66, e27926.	1.5	6
701	Sources of Cells for Hematopoietic Cell Transplantation. , 2019, , 73-84.		1
702	Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy. Biology of Blood and Marrow Transplantation, 2019, 25, 2211-2216.	2.0	13
703	Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?. World Journal of Oncology, 2019, 10, 1-9.	1.5	4
704	Immune reconstitution after T-cell replete HLA-haploidentical transplantation. Seminars in Hematology, 2019, 56, 221-226.	3.4	29
705	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood, 2019, 134, 892-899.	1.4	110
706	Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2019, 10, 1342.	4.8	33
707	Haploidentical hematopoietic stem cell transplantation with postâ€transplant highâ€dose cyclophosphamide in highâ€risk children: A singleâ€center study. Pediatric Transplantation, 2019, 23, e13546.	1.0	9
708	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers. JAMA Oncology, 2019, 5, 1739.	7.1	76
709	Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic. Cellular Immunology, 2019, 346, 103991.	3.0	7

#	Article	IF	Citations
710	Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. Frontiers in Microbiology, 2019, 10, 2235.	3.5	26
711	ST2 and REG3Î± as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide. Frontiers in Immunology, 2019, 10, 2338.	4.8	16
712	Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioningâ€"a matched pair analysis. Annals of Hematology, 2019, 98, 753-762.	1.8	8
713	Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn. Best Practice and Research in Clinical Haematology, 2019, 32, 101112.	1.7	0
714	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
715	Update of the â€œBeijing Protocolâ€•haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 703-707.	2.4	28
716	T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?. Expert Review of Hematology, 2019, 12, 733-752.	2.2	6
717	T Cellâ€“ and B Cellâ€“Mediated Pathology in Chronic Graft-Versus-Host Disease. , 2019, , 251-273.		0
718	Caspofungin for primary antifungal prophylaxis after Tâ€cellâ€“replete haploidentical stem cell transplantation with postâ€transplant cyclophosphamide. European Journal of Haematology, 2019, 102, 357-367.	2.2	6
719	Immunotherapy in pediatric B-cell acute lymphoblastic leukemia. Human Immunology, 2019, 80, 400-408.	2.4	22
720	Donor selection for haploidentical hematopoietic cell transplantationâ€•practice guidance. Advances in Cell and Gene Therapy, 2019, 2, e42.	0.9	0
721	Principles of Hematopoietic Stem Cell Transplantation. , 2019, , 153-163.		2
722	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 1965-1969.	2.0	14
723	Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, 2061-2069.	2.0	12
724	Peripheral Blood Stem Cells versus Bone Marrow for T Cellâ€“Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1810-1817.	2.0	15
725	Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infectious Diseases, The, 2019, 19, e260-e272.	9.1	285
726	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 1798-1802.	2.0	16
727	Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cellâ€“Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 1803-1809.	2.0	20

#	Article	IF	Citations
728	Characterization of Viral Infections after Antithymocyte Globulinâ€“Based Conditioning in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1837-1843.	2.0	6
729	Allodepleted Tâ€cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graftâ€versusâ€host disease (<scp>GVHD</scp>) in the absence of <scp>GVHD</scp> prophylaxis. British Journal of Haematology, 2019, 186, 754-766.	2.5	20
730	Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2019, 10, 1034.	4.8	39
731	Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy. Seminars in Hematology, 2019, 56, 173-182.	3.4	5
732	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood, 2019, 134, 211-215.	1.4	18
733	Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance. Cell Stem Cell, 2019, 25, 185-192.e3.	11.1	46
734	HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. International Journal of Hematology, 2019, 110, 30-38.	1.6	19
735	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. , 2019, , 159-172.		0
736	Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. Transplant Infectious Disease, 2019, 21, e13096.	1.7	46
737	Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1666-1673.	2.0	13
738	Donor-derived CD4+/CCR7+ T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide. Bone Marrow Transplantation, 2019, 54, 1686-1693.	2.4	3
739	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1407-1415.	2.0	42
740	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematology,the, 2019, 6, e183-e193.	4.6	111
741	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. Bone Marrow Transplantation, 2019, 54, 1730-1737.	2.4	19
742	Bone marrow transplant with postâ€transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts. British Journal of Dermatology, 2019, 181, 1238-1246.	1.5	26
743	Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes. Biology of Blood and Marrow Transplantation, 2019, 25, 1395-1406.	2.0	37
744	Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease. Frontiers in Immunology, 2019, 10, 309.	4.8	28
745	Improvements in haploidentical transplantation for sickle cell disease and Î²-thalassaemia. Lancet Haematology,the, 2019, 6, e168-e169.	4.6	6

#	Article	IF	Citations
	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		
746	methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	4.6	200
747	A new standard treatment for prevention of GvHD after HCT?. Lancet Haematology,the, 2019, 6, e113-e114.	4.6	4
748	Impact of cyclosporine A concentration on acute graftâ€vsâ€host disease incidence after haploidentical hematopoietic cell transplantation. European Journal of Haematology, 2019, 103, 10-17.	2.2	17
749	Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. European Journal of Haematology, 2019, 102, 486-493.	2.2	32
750	Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 1465-1471.	2.0	2
751	Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Annals of Hematology, 2019, 98, 1485-1493.	1.8	27
752	Host and Graft Factors Impacting Infection Risk in Hematopoietic Cell Transplantation. Infectious Disease Clinics of North America, 2019, 33, 311-329.	5.1	12
753	High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1701-1709.	2.4	15
754	Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes. Bone Marrow Transplantation, 2019, 54, 1756-1763.	2.4	8
755	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 2019, 54, 1499-1510.	2.4	34
756	Prognostic values of increased B7 family proteins in haploidentical hematopoietic stem cell transplantation patients with aGVHD. International Journal of Hematology, 2019, 109, 451-462.	1.6	6
757	Blockade of TNFÎ± to Improve Human CD34+ Cell Repopulating Activity in Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2018, 9, 3186.	4.8	3
758	Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection afterÂHematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S361-S362.	2.0	0
759	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1340-1346.	2.0	7
760	Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cellâ€“Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. Journal of Immunology, 2019, 202, 2141-2152.	0.8	32
761	Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transplantation, 2019, 54, 1586-1594.	2.4	30
762	How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood, 2019, 134, 1802-1810.	1.4	42
763	Myeloablative vs reduced intensity T-cellâ€“replete haploidentical transplantation for hematologic malignancy. Blood Advances, 2019, 3, 2836-2844.	5.2	38

#	Article	IF	Citations
764	PTCY keeps on giving!. Blood, 2019, 134, 848-849.	1.4	3
765	Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. Blood Advances, 2019, 3, 3351-3359.	5.2	25
766	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Advances, 2019, 3, 2608-2616.	5.2	20
767	The Graft-Versus-Leukemia Effect in AML. Frontiers in Oncology, 2019, 9, 1217.	2.8	75
768	Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned. Transplantation, 2019, 103, 2366-2372.	1.0	19
769	Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding. Frontiers in Immunology, 2019, 10, 2668.	4.8	79
770	Secondary haploidentical hematopoietic stem cell transplantation in patients with relapse or graft failure after initial hematopoietic stem cell transplantation. Annals of Hematology, 2019, 98, 2833-2836.	1.8	0
771	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Frontiers in Immunology, 2019, 10, 2516.	4.8	36
772	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. Transplantation, 2019, 103, 1247-1252.	1.0	3
773	CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation. Frontiers in Immunology, 2019, 10, 2901.	4.8	13
774	Alternative donors: a match for matched sibling donors?. Lancet Haematology,the, 2019, 6, e545-e546.	4.6	1
775	Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies. Frontiers in Immunology, 2019, 10, 2794.	4.8	12
776	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 114-120.	2.0	27
777	Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft?. Seminars in Hematology, 2019, 56, 201-208.	3.4	10
778	Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 785-790.	2.0	38
779	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 827-833.	2.0	23
780	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, 1128-1135.	2.0	38
781	Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis. Expert Review of Hematology, 2019, 12, 47-60.	2.2	19

#	Article	IF	Citations
782	Haploidentical transplantation using lowâ€dose alemtuzumab: Comparison with haploidentical transplantation using lowâ€dose thymoglobulin. European Journal of Haematology, 2019, 102, 256-264.	2.2	14
783	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transplantation, 2019, 54, 1067-1076.	2.4	20
784	Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Reviews, 2019, 34, 34-44.	5.7	67
785	Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative. Biology of Blood and Marrow Transplantation, 2019, 25, 1197-1209.	2.0	120
786	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 522-528.	2.0	48
787	Successful engraftment in recipients of haploidentical stem cells with donor-specific antibodies: role of flow cytometric cross-match. Bone Marrow Transplantation, 2019, 54, 907-910.	2.4	3
788	Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation. Transfusion Medicine Reviews, 2019, 33, 43-50.	2.0	39
789	Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transplantation, 2019, 54, 1049-1057.	2.4	31
790	Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 656-663.	2.0	20
791	Unrelated cord blood transplantation and post-transplant cyclophosphamide. Haematologica, 2019, 104, e77-e78.	3.5	10
792	Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. Cancer, 2019, 125, 1499-1506.	4.1	17
793	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809.	2.4	106
794	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplantation, 2019, 54, 867-876.	2.4	8
795	A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemiaâ€“lymphoma. Bone Marrow Transplantation, 2019, 54, 1266-1274.	2.4	14
796	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica, 2019, 104, 844-854.	3.5	13
797	Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors. Annals of Hematology, 2019, 98, 501-510.	1.8	2
798	The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 606-612.	2.0	10
799	Mesenchymal Stem Cell Therapy in Graft Versus Host Disease. , 2019, , 111-141.		0

#	Article	IF	Citations
800	Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. Seminars in Hematology, 2019, 56, 183-189.	3.4	8
801	T-cell receptor-Î± repertoire of CD8+ T cells following allogeneic stem cell transplantation using next-generation sequencing. Haematologica, 2019, 104, 622-631.	3.5	16
802	Fatal graft-versus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab. Journal of Oncology Pharmacy Practice, 2019, 25, 502-506.	0.9	6
803	Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 45-56.	3.4	26
804	Haploidentical related donor allogeneic hematopoietic stem cell transplantation for patient aged older than 76 years with refractory acute myeloid leukemia. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 175-177.	0.9	1
805	Alternative donor transplantation for acute myeloid leukemia in patients aged â‰¥50 years: young HLA-matched unrelated or haploidentical donor?. Haematologica, 2020, 105, 407-413.	3.5	23
806	Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplantation, 2020, 55, 40-47.	2.4	31
807	Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2020, 55, 317-324.	2.4	13
808	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 12-24.	2.4	94
809	High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide. Bone Marrow Transplantation, 2020, 55, 544-552.	2.4	3
810	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 349-355.	2.4	18
811	Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 230-241.	2.0	35
812	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation, 2020, 55, 283-306.	2.4	128
813	Haploidentical transplantation in highâ€risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). American Journal of Hematology, 2020, 95, 28-37.	4.1	34
814	Acquired Aplastic Anemia. , 2020, , 923-934.		0
815	Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Medicine, 2020, 9, 52-61.	2.8	13
816	The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 123-131.	2.0	9
817	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. Bone Marrow Transplantation, 2020, 55, 763-772.	2.4	16

#	Article	IF	Citations
818	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with postâ€transplantation cyclophosphamide. Transplant Infectious Disease, 2020, 22, e13206.	1.7	13
819	Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis. Bone Marrow Transplantation, 2020, 55, 787-795.	2.4	5
820	Wealth transfer through private placements: Evidence from China. Financial Review, 2020, 55, 199-219.	1.8	2
821	Haematopoietic stem cell transplantation for inborn errors of immunity: 25â€year experience from University of Malaya Medical Centre, Malaysia. Journal of Paediatrics and Child Health, 2020, 56, 379-383.	0.8	5
822	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma â€“ a LWPâ€EBMT study. British Journal of Haematology, 2020, 188, 745-756.	2.5	20
823	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. European Journal of Haematology, 2020, 104, 36-45.	2.2	7
824	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 358-366.	2.0	36
825	Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 651-658.	2.0	18
826	Haploidentical bone marrow transplantation in a child with fatal hepatic failure due to graft-versus-host disease after cord blood transplantation. Leukemia and Lymphoma, 2020, 61, 1263-1264.	1.3	0
827	When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). Annals of Hematology, 2020, 99, 157-165.	1.8	7
828	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for ATL with HTLV-1 Antibody-Positive Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 718-722.	2.0	3
829	Contemporary treatment approaches to CMML â€“ Is allogeneic HCT the only cure?. Best Practice and Research in Clinical Haematology, 2020, 33, 101138.	1.7	4
830	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplantation, 2020, 55, 1050-1058.	2.4	42
831	Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 316-322.	2.0	4
832	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 502-508.	2.0	9
833	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplantation, 2020, 55, 929-938.	2.4	31
834	Hematopoietic Stem Cell Transplantation. , 2020, , 461-469.e3.		4
835	Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia. Brain, 2020, 143, 503-511.	7.6	38

#	Article	IF	Citations
836	Complications of Haploidentical and Mismatched HSC Transplantation. , 2020, , 223-237.		0
837	The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. British Journal of Haematology, 2020, 188, 129-146.	2.5	73
838	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplantation, 2020, 55, 758-762.	2.4	7
839	Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature. Bone Marrow Transplantation, 2020, 55, 1041-1049.	2.4	19
840	Early viral reactivation despite excellent immune reconstitution following haploidentical Bone marrow transplant with postâ€transplant cytoxan for sickle cell disease. Transplant Infectious Disease, 2020, 22, e13222.	1.7	4
841	Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Cancer, 2020, 126, 1004-1015.	4.1	14
843	Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application. Frontiers in Immunology, 2020, 10, 3138.	4.8	7
844	A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation. Medicine (United States), 2020, 99, e21571.	1.0	3
845	Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives. Frontiers in Immunology, 2020, 11, 567020.	4.8	16
846	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2020, 26, 2299-2305.	2.0	4
847	The number of HLA confirmatory tests during unrelated donor search as a driver for the evaluation of back-up haploidentical donor(s). Transfusion and Apheresis Science, 2020, 59, 102766.	1.0	0
848	Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations. Cell Transplantation, 2020, 29, 096368972096590.	2.5	6
849	Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. Lancet Oncology, The, 2020, 21, e477-e487.	10.7	57
850	Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, 2311-2317.	2.0	26
851	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 2075-2081.	2.0	17
852	Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis. Hematology, 2020, 25, 356-365.	1.5	8
853	Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis. Cell Transplantation, 2020, 29, 096368972096477.	2.5	8
854	Does Post-Transplantation Cyclophosphamide Inhibit Graft-versus-Leukemia?. Biology of Blood and Marrow Transplantation, 2020, 26, e243-e244.	2.0	4

#	Article	IF	Citations
855	The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2020, 4, 4812-4821.	5.2	12
856	A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. Biology of Blood and Marrow Transplantation, 2020, 26, e305-e308.	2.0	6
857	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 957-970.	2.2	6
858	Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. Leukemia Research, 2020, 96, 106419.	0.8	11
859	Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A singleâ€center retrospective study. Cancer Medicine, 2020, 9, 6244-6255.	2.8	9
860	Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia and Lymphoma, 2020, 61, 2955-2961.	1.3	10
861	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1915-1922.	2.0	24
862	Longâ€term Followâ€up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics. Pharmacotherapy, 2020, 40, 808-841.	2.6	13
863	Nausea and vomiting during post-transplantation cyclophosphamide administration. International Journal of Hematology, 2020, 112, 577-583.	1.6	2
864	Hematopoietic stem cell transplantation for Langerhans cell histiocytosis: clinical findings and long-term outcomes. Expert Opinion on Orphan Drugs, 2020, 8, 317-328.	0.8	1
865	How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 583564.	4.8	4
866	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. BMC Cancer, 2020, 20, 1140.	2.6	12
867	Haploidentical Stem Cell Transplantation in Lymphomasâ€”Expectations and Pitfalls. Journal of Clinical Medicine, 2020, 9, 3589.	2.4	6
868	Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 3595.	3.7	11
869	Salvage Therapy for Hodgkinâ€™s Lymphoma: A Review of Current Regimens and Outcomes . Journal of Blood Medicine, 2020, Volume 11, 389-403.	1.7	6
870	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES.. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020081.	1.3	10
871	Evolution of the role of haploidentical stem cell transplantation: past, present, and future. Expert Review of Hematology, 2020, 13, 835-850.	2.2	11
872	Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. Journal of Immunology, 2020, 205, 1441-1448.	0.8	9

#	Article	IF	Citations
873	Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 2089-2097.	2.0	8
874	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	4.7	11
875	Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors. Biology of Blood and Marrow Transplantation, 2020, 26, 2082-2088.	2.0	9
876	Review of conditioning regimens for haplo-identical donor transplants using post-transplant cyclophosphamide in recipients of G-CSF mobilised peripheral stem cell. Cancer Treatment Reviews, 2020, 89, 102071.	7.7	3
877	Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Advances, 2020, 4, 3669-3676.	5.2	1
878	Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide and Antithymocyte Globulin from HLA-Mismatched Related Donors for Nonmalignant Diseases. Biology of Blood and Marrow Transplantation, 2020, 26, e286-e291.	2.0	14
879	Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Advances, 2020, 4, 5311-5321.	5.2	15
880	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Advances, 2020, 4, 5078-5088.	5.2	23
881	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1876-1885.	2.0	4
882	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Advances, 2020, 4, 3913-3925.	5.2	52
883	<scp>NK</scp> cell alloreactivity in acute myeloid leukemia in the postâ€transplant cyclophosphamide era. American Journal of Hematology, 2020, 95, 1590-1598.	4.1	7
884	Impact of donor age and kinship on clinical outcomes after T-cellâ€“replete haploidentical transplantation with PT-Cy. Blood Advances, 2020, 4, 3900-3912.	5.2	30
885	Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. Blood Advances, 2020, 4, 4430-4437.	5.2	23
886	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Advances, 2020, 4, 1770-1779.	5.2	92
887	Is unrelated donor or haploidentical hematopoietic transplantation preferred for patients with acute myeloid leukemia in remission?. Haematologica, 2020, 105, 252-254.	3.5	4
888	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. Annals of Hematology, 2020, 99, 1341-1350.	1.8	7
889	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplantation, 2020, 55, 2147-2159.	2.4	24
890	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. Journal of Hematology and Oncology, 2020, 13, 46.	17.0	68

#	Article	IF	Citations
891	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Advances, 2020, 4, 2073-2083.	5.2	39
892	A Case Series of Post-Transplantation Cyclophosphamide in Unrelated Donor Hematopoietic Cell Transplantation for Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, e222-e226.	2.0	6
893	Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach . Journal of Blood Medicine, 2020, Volume 11, 141-162.	1.7	13
894	Complete remission and proviral load negativization after allogeneicâ€SCT in a patient with Adult Tâ€cell lymphoma: Case report. Transplant Infectious Disease, 2020, 22, e13350.	1.7	0
895	Second Allogeneic Hematopoietic Stem Cell Transplantation After Donor Replacement in Children With Severe Aplastic Anemia. Transplantation Proceedings, 2020, 52, 1860-1863.	0.6	0
896	T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies. Frontiers in Pediatrics, 2020, 8, 282.	1.9	20
897	Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 181-188.	0.9	22
898	The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Bone Marrow Transplantation, 2020, 55, 1946-1954.	2.4	14
899	Risk factors associated with early viral reactivation following haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide: a pilot study. Annals of Hematology, 2020, 99, 1137-1139.	1.8	2
900	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplantation, 2020, 55, 1347-1356.	2.4	9
901	Posttransplantation Lymphoproliferative Disease Treated by Retransplantation. Case Reports in Immunology, 2020, 2020, 1-4.	0.4	2
902	Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 191.	4.8	30
903	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 147.	4.8	39
904	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1670-1678.	2.0	17
905	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. Biology of Blood and Marrow Transplantation, 2020, 26, 1679-1688.	2.0	25
906	How Allogeneic Hematopoietic Stem Cell Transplantation has Evolved Over Time: 30-Yearsâ€™ Experience at a Single Institution. Acta Medica Portuguesa, 2020, 33, 116.	0.4	0
907	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigenâ€“mismatched donors. Blood, 2020, 136, 1499-1506.	1.4	16
908	Introduction of principles of blood management to healthy donor bone marrow harvesting. Vox Sanguinis, 2020, 115, 802-812.	1.5	5

#	Article	IF	Citations
909	Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biology of Blood and Marrow Transplantation, 2020, 26, 1923-1929.	2.0	34
910	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. Journal of Hematology and Oncology, 2020, 13, 87.	17.0	44
911	Photodepletion with 2-Se-Cl prevents lethal graft-versus-host disease while preserving antitumor immunity. PLoS ONE, 2020, 15, e0234778.	2.5	1
912	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplantation, 2020, 55, 1773-1783.	2.4	35
913	Selecting patients with primary myelofibrosis for stem cell transplant using clinical, mutational, and transplantâ€specific profiles. Advances in Cell and Gene Therapy, 2020, 3, e80.	0.9	0
914	Total Marrow Irradiation. , 2020, , .		6
915	Is there no place like home for an allogeneic stem cell transplant?. Bone Marrow Transplantation, 2020, 55, 855-856.	2.4	1
916	Stem cell transplant for the treatment of myelofibrosis. Expert Review of Hematology, 2020, 13, 363-374.	2.2	4
917	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer, 2020, 126, 2193-2205.	4.1	33
918	Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?. British Journal of Haematology, 2020, 189, 408-423.	2.5	29
919	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. Leukemia, 2020, 34, 1907-1923.	7.2	20
920	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. Cytotherapy, 2020, 22, 158-165.	0.7	10
921	Successful engraftment of haploidentical bone marrow with postâ€transplantation cyclophosphamide in patients with aplastic anemia. Pediatric Transplantation, 2020, 24, e13652.	1.0	3
922	Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. Biology of Blood and Marrow Transplantation, 2020, 26, 1179-1188.	2.0	49
923	Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Frontiers in Immunology, 2020, 11, 636.	4.8	27
924	Influence of HLA 1â€“3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation. Annals of Hematology, 2020, 99, 1099-1110.	1.8	1
925	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1332-1341.	2.0	24
926	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2020, 26, 1312-1317.	2.0	49

#	Article	IF	Citations
927	Failure to Prevent Severe Graft-Versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Chronic Granulomatous Disease. Journal of Clinical Immunology, 2020, 40, 619-624.	3.8	19
928	Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 208-213.	0.9	13
929	Comparative Efficacy and Clinical Outcomes of Haploidentical Stem Cell Transplantation to Other Stem Sources for Treatment in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis. Cell Transplantation, 2020, 29, 096368972090496.	2.5	11
930	Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Advances, 2020, 4, 1242-1249.	5.2	21
931	A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis. Acta Haematologica, 2021, 144, 158-165.	1.4	23
932	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. Leukemia, 2021, 35, 585-594.	7.2	18
933	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Acta Haematologica, 2021, 144, 66-73.	1.4	11
934	Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study. Frontiers of Medicine, 2021, 15, 108-115.	3.4	3
935	Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplantation, 2021, 56, 853-862.	2.4	42
936	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta OncolÃ³gica, 2021, 60, 466-474.	1.8	4
937	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Annals of Hematology, 2021, 100, 541-553.	1.8	25
938	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 622-634.	2.4	9
939	Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia. Bone Marrow Transplantation, 2021, 56, 586-595.	2.4	15
940	Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes. Journal of Clinical Immunology, 2021, 41, 414-426.	3.8	12
941	Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation. Cellular and Molecular Immunology, 2021, 18, 905-918.	10.5	11
942	PTCy and â€œThe Story of the Three Bearsâ€• Bone Marrow Transplantation, 2021, 56, 765-766.	2.4	2
943	Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. Bone Marrow Transplantation, 2021, 56, 883-889.	2.4	10
944	Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transplantation, 2021, 56, 1291-1296.	2.4	14

#	Article	IF	Citations
945	Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible. Transplantation and Cellular Therapy, 2021, 27, 259.e1-259.e6.	1.2	11
946	Comparison of myeloablative and reduced intensity conditioning regimens in haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 741-744.	2.4	3
947	Postâ€transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLAâ€identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 209-218.	4.1	26
948	Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching. Bone Marrow Transplantation, 2021, 56, 818-827.	2.4	30
949	Critical Care of Hematopoietic Stem Cell Transplant Patients. Critical Care Clinics, 2021, 37, 29-46.	2.6	9
950	Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors. Annals of Hematology, 2021, 100, 181-187.	1.8	6
951	Cytokine syndromes associated with hematopoietic cellular therapy. Advances in Cell and Gene Therapy, 2021, 4, .	0.9	1
952	Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose) Tj ETQq1 1 0.784314 rgBT /Overlock 1 anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood. Bone Marrow Transplantation, 2021, 56, 705-708.	2.4	20
953	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 6-20.	1.2	45
954	Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study. American Journal of Hematology, 2021, 96, 98-109.	4.1	17
955	Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease. Bone Marrow Transplantation, 2021, 56, 492-504.	2.4	18
956	Exploring the NK cell platform for cancer immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 85-100.	27.6	605
957	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Advances, 2021, 5, 352-364.	5.2	58
958	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. Cancer Biology and Medicine, 2021, 18, 0-0.	3.0	6
959	Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major. Cell Transplantation, 2021, 30, 096368972199480.	2.5	3
960	Myeloablative haploidentical tâ€cell replete hematopoietic cell transplantation with postâ€transplant cyclophosphamide in highâ€risk hematological malignancies: Bending the learning curve in a middleâ€income setting. Advances in Cell and Gene Therapy, 2021, 4, e106.	0.9	0
961	Graft-Versus-Host Disease (GvHD) Prophylaxis. , 2021, , 153-186.		0
962	Engraftment. , 2021, , 225-230.		0

#	Article	IF	Citations
963	Methotrexate Based Regimen versus Post-Transplant Cyclophosphamide in Allogeneic Hematopoietic Stem Cell Transplantation (Clinical Outcome), Egyptian Experience. The Egyptian Journal of Hospital Medicine, 2021, 82, 727-732.	0.1	0
964	The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma. Clinical Hematology International, 2021, 3, 116.	1.7	1
965	HSCT in Benign Hematological Disorders. Organ and Tissue Transplantation, 2021, , 115-163.	0.0	0
966	CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. Journal of Clinical Investigation, 2021, 131, .	8.2	35
967	Selection of Suitable Alternative Donor in the Absence of Matched Sibling Donor: A Retrospective Single-Center Study to Compare between Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation. International Journal of Hematology-Oncology and Stem Cell Research, 2021, 15, 51-60.	0.3	2
968	Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation. Therapeutic Advances in Hematology, 2021, 12, 204062072199812.	2.5	4
969	HLA-mismatched haploidentical transplantation using low-dose alemtuzumab. Journal of Hematopoietic Cell Transplantation, 2021, 10, 23-29.	0.1	1
970	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. International Journal of Hematology, 2021, 113, 712-722.	1.6	1
971	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
972	Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 373-385.	1.6	11
973	Role of Stem Cell Transplantation in Multiple Myeloma. Cancers, 2021, 13, 863.	3.7	17
974	Disease Risk Comorbidity Index for Patients Receiving Haploidentical Allogeneic Hematopoietic Transplantation. Engineering, 2021, 7, 162-169.	6.7	11
975	Grade 3â€“4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation. Leukemia and Lymphoma, 2021, 62, 1982-1989.	1.3	5
976	Allogenic hematopoietic stem cell transplantation in sickle cell disease. Transfusion and Apheresis Science, 2021, 60, 103057.	1.0	1
977	Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. Annals of Hematology, 2021, 100, 1295-1301.	1.8	2
978	Thiotepaâ€“busulfanâ€“fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1593-1602.	2.4	8
979	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplantÂmeasurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia, 2021, 35, 2232-2242.	7.2	6
980	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Advances, 2021, 5, 1154-1163.	5.2	26

#	Article	IF	Citations
981	Expect the unexpected. Blood, 2021, 137, 3163-3164.	1.4	0
982	Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies. Bone Marrow Transplantation, 2021, 56, 1518-1534.	2.4	9
983	Acute Lymphoblastic Leukemia in Adolescents and Young Adults. , 0, , .		0
984	Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Advances, 2021, 5, 1360-1368.	5.2	39
985	Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells. Bone Marrow Transplantation, 2021, 56, 1818-1827.	2.4	2
986	Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases. Transplantation and Cellular Therapy, 2021, 27, 492.e1-492.e6.	1.2	7
988	Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplantation and Cellular Therapy, 2021, 27, 493.e1-493.e8.	1.2	5
989	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 452-466.	1.2	24
991	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. Bone Marrow Transplantation, 2021, 56, 1842-1849.	2.4	4
992	Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. Transplantation and Cellular Therapy, 2021, 27, 478.e1-478.e5.	1.2	12
993	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	1.4	85
994	Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study. Frontiers in Medicine, 2021, 8, 630160.	2.6	6
995	Outcome of Tâ€cellâ€“replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 2507-2514.	4.1	8
996	Post-Transplant Cyclophosphamide and Tacrolimusâ€"Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Journal of Clinical Medicine, 2021, 10, 1173.	2.4	10
997	Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 666091.	2.8	11
998	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. Transplantation and Cellular Therapy, 2021, 27, 334.e1-334.e11.	1.2	23
999	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. Transplantation and Cellular Therapy, 2021, 27, 328.e1-328.e6.	1.2	2
1000	GVHD Prophylaxis 2020. Frontiers in Immunology, 2021, 12, 605726.	4.8	49

#	Article	IF	Citations
1002	Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience. Transplantation and Cellular Therapy, 2021, 27, 331.e1-331.e7.	1.2	10
1003	Which is better, HLA-matched sibling or haploidentical transplantation?. Cellular and Molecular Immunology, 2021, 18, 1347-1347.	10.5	5
1004	Application of Stem Cell Therapy in Myelofibrosis. Hematology/Oncology Clinics of North America, 2021, 35, 391-407.	2.2	6
1005	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood, 2021, 138, 273-282.	1.4	88
1006	Realâ€world experience: Introduction of T cell replete haploidentical transplantations in a single center. EJHaem, 2021, 2, 440-448.	1.0	1
1007	Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Medical Mycology, 2021, 59, 970-979.	0.7	20
1008	Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders. Bone Marrow Transplantation, 2021, 56, 2248-2258.	2.4	6
1009	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 428.e1-428.e9.	1.2	11
1010	Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant. Frontiers in Immunology, 2021, 12, 674658.	4.8	10
1011	Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 424.e1-424.e9.	1.2	22
1012	Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2021, 23, e13626.	1.7	5
1013	Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 2408-2415.	1.3	2
1014	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. Frontiers in Immunology, 2021, 12, 659595.	4.8	44
1015	Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with High-Risk Leukemia Using a Reduced-Intensity Conditioning Regimen and Peripheral Blood as the Stem Cell Source. Transplantation and Cellular Therapy, 2021, 27, 427.e1-427.e7.	1.2	11
1016	Graftâ€‹versusâ€‹host disease risk after chimeric antigen receptor Tâ€‹cell therapy: the diametric opposition of T cells. British Journal of Haematology, 2021, 195, 660-668.	2.5	37
1017	Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation, 2021, 56, 2432-2444.	2.4	33
1018	Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate. Transplantation and Cellular Therapy, 2021, 27, 429.e1-429.e7.	1.2	8
1019	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica, 2022, 107, 1054-1063.	3.5	20

#	Article	IF	Citations
1020	National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2021, 39, 1971-1982.	1.6	90
1021	60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Research, 2021, 81, 4373-4384.	0.9	19
1022	Incidence and impact of community respiratory viral infections in postâ€transplant cyclophosphamideâ€based graftâ€versusâ€host disease prophylaxis and haploidentical stem cell transplantation. British Journal of Haematology, 2021, 194, 145-157.	2.5	12
1023	Reduced dose of PTCy followed by adjuvant Î±-galactosylceramide enhances GVL effect without sacrificing GVHD suppression. Scientific Reports, 2021, 11, 13125.	3.3	6
1024	Prophylactic pretransplant ganciclovir to reduce cytomegalovirus infection after hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
1025	Increasing Donor Options in Allogenic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 1951-1954.	1.6	1
1026	Encouraging Outcomes of Alternate Donor Hematopoietic Stem Cell Transplant in Pediatric High Risk/Relapsed Leukemias. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, e1148-e1152.	0.6	0
1027	Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT. JCI Insight, 2021, 6, .	5.0	19
1028	Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation. Journal of Clinical Medicine, 2021, 10, 2843.	2.4	2
1029	Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. JACC: CardioOncology, 2021, 3, 250-259.	4.0	48
1030	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. Frontiers in Medicine, 2021, 8, 604085.	2.6	13
1031	Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Advances, 2021, 5, 2650-2659.	5.2	29
1032	Immune tolerance with combined allogeneic haploâ€identical haematopoietic stem cell transplant and renal transplant. British Journal of Haematology, 2021, 194, 779-783.	2.5	0
1033	Postâ€transplant cyclophosphamide limits reactive donor T cells and delays the development of graftâ€versusâ€host disease in a humanized mouse model. Immunology, 2021, 164, 332-347.	4.4	7
1034	Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 614.e1-614.e8.	1.2	2
1035	FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases. Transplantation and Cellular Therapy, 2021, 27, 915.e1-915.e8.	1.2	4
1036	Single-cell profiling reveals the dynamics of cytomegalovirus-specific T cells in haploidentical hematopoietic stem cell transplantation. Haematologica, 2021, 106, 2768-2773.	3.5	6
1037	Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach. Journal of Fungi (Basel, Switzerland), 2021, 7, 588.	3.5	17

#	Article	IF	Citations
1038	Successful haploidentical transplantation using plasma exchange and post-transplantation cyclophosphamide for severe aplastic anemia patients with anti-human leukocyte antigen donor-specific antibodies. Annals of Hematology, 2021, 100, 2381-2385.	1.8	2
1039	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. Transplantation and Cellular Therapy, 2021, 27, 619.e1-619.e8.	1.2	15
1040	A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia and Lymphoma, 2021, 62, 3181-3191.	1.3	4
1041	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 545-557.	1.2	72
1042	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. Bone Marrow Transplantation, 2021, 56, 2763-2770.	2.4	25
1043	Phase <scp>II</scp> clinical trial of one dose of postâ€transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matchedâ€unrelated donor transplantation. American Journal of Hematology, 2021, 96, E396-E398.	4.1	4
1044	Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 660.e1-660.e8.	1.2	5
1045	Single-Arm Non-Blinded Multicenter Clinical Trial on T-Cell-Replete Haploidentical Stem Cell Transplantation Using Low-Dose Antithymocyte Globulin for Relapsed and Refractory Pediatric Acute Leukemia. Kurume Medical Journal, 2019, 66, 161-168.	0.1	0
1046	Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Advances, 2021, 5, 4064-4072.	5.2	17
1047	A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. Cytotherapy, 2021, 23, 1007-1016.	0.7	4
1048	Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the SociÃ©tÃ© Francophone de Greffe de Moelle et de Therapie Cellulaire. Bone Marrow Transplantation, 2021, 56, 2849-2856.	2.4	2
1049	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplantation and Cellular Therapy, 2021, 27, 921.e1-921.e10.	1.2	11
1050	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. Transplantation and Cellular Therapy, 2021, 27, 912.e1-912.e6.	1.2	3
1051	The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models. Frontiers in Immunology, 2021, 12, 715424.	4.8	15
1052	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. Journal of Clinical Medicine, 2021, 10, 3790.	2.4	10
1053	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
1054	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. Leukemia and Lymphoma, 2021, 62, 3373-3383.	1.3	12
1055	How antithymocyte globulin, a polyclonal soup of the past century, when carefully dosed, has become crucial for hematopoietic stem cell transplantation with haplo-identical donors in the 21st century. Science Bulletin, 2021, 66, 2445-2445.	9.0	0

#	Article	IF	Citations
1056	Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 909.e1-909.e6.	1.2	7
1057	Is Haploidentical Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide Feasible in Sub-Saharan Africa?. Transplantation and Cellular Therapy, 2021, , .	1.2	1
1058	Antigen Specific Regulatory T Cells in Kidney Transplantation and Other Tolerance Settings. Frontiers in Immunology, 2021, 12, 717594.	4.8	15
1059	Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts. Transplantation and Cellular Therapy, 2021, 27, 782.e1-782.e7.	1.2	13
1060	Nonclassical manifestations of acute GVHD. Blood, 2021, 138, 2165-2172.	1.4	25
1061	Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia. Bone Marrow Transplantation, 2021, 56, 3042-3048.	2.4	4
1062	Donor source and postâ€transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency. British Journal of Haematology, 2022, 196, 169-178.	2.5	18
1063	A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform. Frontiers in Immunology, 2021, 12, 744430.	4.8	3
1064	Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults. Blood Reviews, 2022, 52, 100886.	5.7	3
1065	Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using postâ€transplant cyclophosphamide. Cancer Medicine, 2021, 10, 7194-7202.	2.8	4
1066	Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2021, 27, 760-767.	1.2	18
1067	Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2021, 27, 999.e1-999.e10.	1.2	6
1068	Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Cancer Management and Research, 2021, Volume 13, 7411-7427.	1.9	4
1069	Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Advances, 2021, 5, 5599-5607.	5.2	29
1070	Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients. Transplantation and Cellular Therapy, 2021, 27, 879.e1-879.e3.	1.2	0
1071	Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2021, 27, 861.e1-861.e7.	1.2	0
1072	Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation. Life, 2021, 11, 102.	2.4	8
1073	Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis. Annals of Hematology, 2021, 100, 529-540.	1.8	8

#	Article	IF	Citations
1074	Graft Versus Host Disease: Management of Acute and Chronic Disease. Organ and Tissue Transplantation, 2021, , 365-393.	0.0	0
1075	Pediatric Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 577-616.	0.0	0
1076	Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently. Clinical Hematology International, 2021, 3, 153.	1.7	14
1077	Outcomes of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 689-730.	0.0	0
1078	Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation. Organ and Tissue Transplantation, 2021, , 395-419.	0.0	0
1079	The Toll of Prophylaxis: Cytomegalovirus Infection in the Haploidentical Donor and Post-transplant Cyclophosphamide Era. , 2021, 18, .		0
1080	Evolving Therapeutic Options for Chronic Graftâ€versusâ€Host Disease. Pharmacotherapy, 2020, 40, 756-772.	2.6	11
1082	Donor Selection for Adults and Pediatrics. , 2019, , 87-97.		8
1083	Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. Biology of Blood and Marrow Transplantation, 2020, 26, 1492-1496.	2.0	16
1084	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
1085	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia, 2020, 34, 2766-2775.	7.2	30
1086	Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 596-604.	2.4	28
1087	Clinical Factors Affecting the Dose Conversion Ratio from Intravenous to Oral Tacrolimus Formulation among Pediatric Hematopoietic Stem Cell Transplantation Recipients. Therapeutic Drug Monitoring, 2020, 42, 803-810.	2.0	4
1088	Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective. Journal of Pediatric Hematology/Oncology, 2021, 43, e1033-e1036.	0.6	13
1089	HSCT-Based Approaches for Tolerance Induction in Renal Transplant. Transplantation, 2017, 101, 2682-2690.	1.0	21
1090	Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight, 2016, 1, .	5.0	111
1091	Unique features and clinical importance of acute alloreactive immune responses. JCI Insight, 2018, 3, .	5.0	9
1092	Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. Journal of Clinical Investigation, 2019, 129, 2189-2191.	8.2	11

#	Article	IF	Citations
1093	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation, 2016, 126, 3363-3376.	8.2	399
1094	Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematology American Society of Hematology Education Program, 2012, 2012, 49-55.	2.5	13
1095	Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematology American Society of Hematology Education Program, 2012, 2012, 49-55.	2.5	13
1096	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood, 2018, 131, 247-262.	1.4	164
1097	How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Hematology American Society of Hematology Education Program, 2019, 2019, 513-521.	2.5	19
1098	Are we underutilizing bone marrow and cord blood? Review of their role and potential in the era of cellular therapies. F1000Research, 2020, 9, 26.	1.6	11
1099	Advances in treating acute myeloid leukemia. F1000prime Reports, 2014, 6, 96.	5.9	28
1100	First Report of Severe Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant in a Patient With Myelodysplastic Syndrome Treated With Atezolizumab: Literature Review. World Journal of Oncology, 2020, 11, 112-115.	1.5	5
1103	Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget, 2017, 8, 63574-63586.	1.8	32
1104	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget, 2018, 9, 11451-11464.	1.8	46
1105	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. Oncotarget, 2018, 9, 33528-33535.	1.8	17
1106	Curative Therapies for Sickle Cell Disease. Ochsner Journal, 2019, 19, 131-137.	1.1	20
1107	Translational and clinical advances in acute graft-versus-host disease. Haematologica, 2020, 105, 2550-2560.	3.5	21
1108	History of hematopoietic cell transplantation: challenges and progress. Haematologica, 2020, 105, 2716-2729.	3.5	54
1109	Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies. Frontiers in Immunology, 2020, 11, 607030.	4.8	14
1110	HLA Mismatch Allogeneic Blood and Marrow Transplantation. Korean Journal of Medicine, 2014, 86, 1.	0.3	4
1111	Blood and Bone Marrow Transplantation in India: Past, Present, and Future. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 308-311.	0.2	8
1112	Haploidenticalvscord blood transplantation for adults with acute myelogenous leukemia. World Journal of Stem Cells, 2014, 6, 371.	2.8	9

#	Article	IF	Citations
1113	Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World Journal of Transplantation, 2013, 3, 99.	1.6	36
1114	Overview of the progress on haploidentical hematopoietic transplantation. World Journal of Transplantation, 2016, 6, 665.	1.6	14
1115	Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma. World Journal of Transplantation, 2018, 8, 252-261.	1.6	3
1116	Advances in haploidentical stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 237-241.	0.7	7
1117	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 599-634.	4.9	33
1118	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. Transplantation and Cellular Therapy, 2022, 28, 50.e1-50.e8.	1.2	11
1119	Outcomes of unrelated donor stem cell transplantation with or without anti-thymocyte globulin used as graft-versus-host disease prophylaxis in patients with acute leukaemia and myelodysplastic syndrome. Medicina ClÃ¬nica (English Edition), 2021, 157, 380-384.	0.2	0
1120	Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. Blood, 2022, 139, 3583-3593.	1.4	10
1121	Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Annals of Hematology, 2022, 101, 1145-1147.	1.8	4
1122	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 260-269.	0.4	4
1123	Antiâ€thymocyte globulin and postâ€transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. European Journal of Haematology, 2022, 108, 61-72.	2.2	9
1124	Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis. Bone Marrow Transplantation, 2022, 57, 65-71.	2.4	2
1125	Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. Leukemia and Lymphoma, 2021, 62, 3474-3483.	1.3	7
1126	Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complicationsâ€“A single center experience from India. Transplantation and Cellular Therapy, 2022, 28, 45.e1-45.e8.	1.2	6
1127	Resultados del trasplante de progenitores hematopoyÃ©ticos de donante no emparentado con o sin globulina antitimocÃ¬tica como profilaxis de la enfermedad del injerto contra receptor en pacientes con leucemia aguda y sÃ¬ndrome mielodisplÃ¡sico. Medicina ClÃ¬nica, 2021, 157, 380-384.	0.6	0
1128	New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opinion on Therapeutic Targets, 2021, 25, 761-771.	3.4	10
1129	Cytomegalovirus in Haematological Tumours. Frontiers in Immunology, 2021, 12, 703256.	4.8	11
1130	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia, 2022, 36, 856-864.	7.2	26

#	Article	IF	Citations
1131	A Comparison of the Clinical Outcomes of Haploidentical Transplantation and Other Graft Sources in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 174-191.	0.4	4
1132	Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease. Clinical Drug Investigation, 2021, 41, 929-939.	2.2	6
1133	Allogeneic Hematopoietic Cell Transplantation from an HLA-mismatched Family Donor: The Current Status and Future. Journal of the Korean Medical Association, 2009, 52, 819.	0.3	0
1134	Hematopoietic Cell Transplantation from Partially HLA-Mismatched (HLA-Haploidentical) Related Donors. , 2010, , 299-343.		0
1136	Myeloablative Transplant (HCT). , 2012, , 169-186.		0
1137	Reduced-Intensity and Non-Myeloablative Conditioning Followed by Hematopoietic Cell Transplantation. , 2012, , 187-217.		0
1138	Total Body Irradiation. , 2012, , 345-360.		1
1139	Alternative Sources of Hematopoietic Stem Cells and Their Clinical Applications. , 2013, , 1289-1306.		0
1140	Hematopoietic Cell Transplantation (HCT). , 2013, , 211-228.		0
1141	Current status of GVHD control in HLA mismatched stem cell transplantation from family donor. Journal of Hematopoietic Cell Transplantation, 2013, 2, 94-100.	0.1	0
1142	Hematopoietic stem cell transplantation in children: current practice. Drugs and Cell Therapies in Hematology, 2013, 2, 43.	0.1	0
1143	Hematopoietic Stem Cell Transplantation. , 2014, , 485-492.e2.		0
1144	Immunotherapy of Cancer Employing Î³ Î´-T Cells: New Challenges, New Opportunities. The Open Immunology Journal, 2014, 7, 156-162.	1.5	0
1145	Rapamycin-Resistant T Cells and Pentostatin-Based Immuno-Selective Conditioning for the Allogeneic T Cell Therapy of Cancer. Cancer Drug Discovery and Development, 2015, , 281-302.	0.4	0
1148	Encouraging Outcomes in African-American Patients with Use of Post-Transplant Cyclophosphamide after HLA Mismatched Hematopoietic Stem Cell Transplant. Blood, 2015, 126, 3228-3228.	1.4	0
1149	Allogene Stammzelltransplantation bei Ãlteren komorbiden Patienten. , 2016, , 1-11.		0
1150	Prevention of Acute Graft-Versus-Host Reaction after Allogeneic Unrelated Hematopoietic Stem Cell Transplantation: Comparison of Effectiveness of Treatment Regimens Based on Anti-Thymocyte Globulin and Cyclophosphamide. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 391-397.	0.4	1
1151	Applications of Haploidentical SCT in Pediatric Patients. Pancreatic Islet Biology, 2017, , 149-178.	0.3	0

#	Article	IF	Citations
1152	Graft Failure and Rejection in Haploidentical Stem Cell Transplantation. Pancreatic Islet Biology, 2017, , 17-41.	0.3	0
1153	Outcome of Haploidentical Stem Cell Transplantation in Patients with Lymphoma. Pancreatic Islet Biology, 2017, , 119-140.	0.3	0
1154	An Overview of the Prophylaxis and Treatment of GvHD in Haploidentical SCT. Pancreatic Islet Biology, 2017, , 57-65.	0.3	0
1157	Limitations and Unique Complications of Umbilical Cord Blood Transplantation. , 2017, , 257-291.		0
1158	Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease. , 2018, , 283-302.		0
1159	Overview of Hematopoietic Stem Cell Transplantation for Nonmalignant Diseases. , 2018, , 163-184.		1
1160	Allogene Stammzelltransplantation bei Ãlteren komorbiden Patienten. , 2018, , 113-123.		0
1161	Overcoming HLA Barrier in Hematopoietic Stem Cell Transplantation. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 579-585.	0.0	0
1162	Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma. World Journal of Transplantation, 2018, 8, 252-261.	1.6	0
1163	Comparative Study of Mycophenolate Mofetil and Methotrexate in Graft-Versus-Host Disease Prophylaxis in Adult Recipients of Related and Unrelated Allo-HSCT. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 43-50.	0.4	0
1164	Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma. , 2019, , 231-243.		0
1165	Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies. Clinical Hematology International, 2019, 1, 134-141.	1.7	2
1166	Stem Cell Transplantation for Pediatric ALL. , 2020, , 151-161.		1
1167	Immunosuppressive Therapy and Immunomodulation in Stem Cell Transplantation. Organ and Tissue Transplantation, 2020, , 1-26.	0.0	0
1168	Pediatric Bone Marrow Transplantation. Organ and Tissue Transplantation, 2020, , 1-38.	0.0	0
1169	Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody. BLOOD CELL THERAPY / the Official Journal of APBMT, 2020, 3, .	0.1	1
1170	Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed Metastatic Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2020, 42, 499-499.	0.6	3
1171	Haploidentical Family Donor Transplantation for Pediatric Hematologic Malignancies. Clinical Pediatric Hematology-Oncology, 2021, 28, 67-74.	0.2	1

#	Article	IF	Citations
1172	Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective. Frontiers in Oncology, 2021, 11, 758512.	2.8	11
1173	Changing trends in the therapy of acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101333.	1.7	3
1174	Total Marrow and Lymphoid Irradiation in Haploidentical Hematopoietic Cell Transplant. , 2020, , 123-133.		1
1175	Unmanipulated haploidentical stem cell transplantation using low-dose ATG and steroid for high-risk diseases. Journal of Hematopoietic Cell Transplantation, 2020, 9, 100-109.	0.1	0
1176	Outcomes of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2020, , 1-43.	0.0	0
1177	Successful engraftment of haploidentical stem cell transplant with postâ€transplantation cyclophosphamide in a patient with adenosine deaminase deficiency. Pediatric Transplantation, 2021, 25, e13954.	1.0	1
1178	Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitis. Hematology, Transfusion and Cell Therapy, 2022, 44, 163-168.	0.2	5
1179	Graft Versus Host Disease: Management of Acute and Chronic Disease. Organ and Tissue Transplantation, 2021, , 1-30.	0.0	0
1180	HSCT in Benign Hematological Disorders. Organ and Tissue Transplantation, 2021, , 1-49.	0.0	0
1181	Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients. Journal of Oncology Pharmacy Practice, 2022, 28, 31-38.	0.9	1
1182	T-cell replete Haplo-identical HSCT with Post transplant Cyclophosphamide for Hemoglobinopathies: A retrospective analysis from a single center. BLOOD CELL THERAPY / the Official Journal of APBMT, 2020, 4, .	0.1	0
1183	Total Marrow Irradiation: Redefining the Role of Radiotherapy in Bone Marrow Transplantation. , 2020, , 1-27.		2
1184	T-cell replete haploidentical stem cell transplantation for children with relapsed or refractory acute leukemia.. Journal of Hematopoietic Cell Transplantation, 2020, 9, 23-31.	0.1	0
1185	ICU Complications of Hematopoietic Stem Cell Transplant, Including Graft vsÂHost Disease. , 2020, , 599-609.		1
1186	Pediatric Bone Marrow Transplantation. Organ and Tissue Transplantation, 2020, , 1-41.	0.0	0
1187	Reconstitution of T-cell-mediated immunity in patients after allogeneic stem cell transplantation. Gematologiya I Transfuziologiya, 2020, 65, 24-38.	0.6	4
1188	Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies. Frontiers in Immunology, 2021, 12, 733326.	4.8	3
1189	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone Marrow Transplantation, 2021, , .	2.4	2

#	Article	IF	Citations
1190	Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes . Cancer Management and Research, 2020, Volume 12, 12287-12300.	1.9	1
1193	Development of therapeutic agents for older patients with acute myelogenous leukemia. Current Opinion in Investigational Drugs, 2010, 11, 669-77.	2.3	10
1194	Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives. Stem Cell Investigation, 2015, 2, 20.	3.0	1
1195	A Survey of Infection in Allogenic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. International Journal of Organ Transplantation Medicine, 2018, 9, 112-116.	0.5	2
1196	Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies-A meta-analysis and systematic review. American Journal of Blood Research, 2020, 10, 1-10.	0.6	3
1200	Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood, 2022, 139, 608-623.	1.4	42
1201	Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis. Transplantation and Cellular Therapy, 2022, 28, 158.e1-158.e9.	1.2	4
1202	Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Leukemia and Lymphoma, 2022, 63, 222-226.	1.3	0
1203	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplantation, 2021, , .	2.4	2
1204	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 111.e1-111.e8.	1.2	16
1205	Allogeneic transplant graft source â€“ conditioning â€“ GVHD prophylaxis: donâ€™t mix and match!. Leukemia and Lymphoma, 2021, , 1-3.	1.3	1
1206	Impact of graft-versus-host disease prophylaxis on immune reconstitution in patients after allogeneic hematopoietic stem cell transplantation. Medical Immunology (Russia), 2021, 23, 1125-1136.	0.4	2
1207	Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in a child with neuroblastoma relapse after autologous peripheral blood stem cell transplantation. Pediatric Blood and Cancer, 2022, 69, e29439.	1.5	0
1208	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2022, 40, 356-368.	1.6	79
1209	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Advances, 2022, 6, 920-930.	5.2	16
1210	Haploidentical Hematopoietic Stem Cell Transplant Using Post-transplant Cyclophosphamide: A Single-Center Initial Experience in Vietnam. BLOOD CELL THERAPY / the Official Journal of APBMT, 2021, 4, .	0.1	0
1212	Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study. Clinical Infectious Diseases, 2022, 75, 795-804.	5.8	20
1213	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 399-406.	2.4	9

#	Article	IF	Citations
1214	Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation. Transplantation and Cellular Therapy, 2022, 28, 213.e1-213.e6.	1.2	10
1215	Bowel wall thickness is a strong predictor of steroid-refractory acute graft-versus-host disease with gut involvement after allo-HSCT. International Journal of Hematology, 2022, 115, 545-552.	1.6	1
1216	HLA 1â€“3 antigenâ€mismatched related peripheral blood stem cells transplantation using lowâ€dose antithymocyte globulin versus unrelated cord blood transplantation. American Journal of Hematology, 2022, 97, 311-321.	4.1	2
1217	Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. Annals of Hematology, 2022, 101, 643-653.	1.8	6
1218	The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands. European Journal of Haematology, 2022, 108, 327-335.	2.2	4
1219	Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkinâ€™s Lymphoma: Recent Advances and Outcomes. Journal of Personalized Medicine, 2022, 12, 125.	2.5	4
1220	What are the risks and benefit of a transplant for elderly patients?. Journal of Illusion, 2022, 11, 22-35.	0.1	0
1221	The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted Agents. Cancer Journal (Sudbury, Mass), 2022, 28, 78-84.	2.0	0
1222	Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation. Blood Advances, 2022, 6, 3053-3057.	5.2	7
1223	Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC. Transplantation and Cellular Therapy, 2022, 28, 204.e1-204.e10.	1.2	6
1224	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 562-571.	2.4	16
1225	Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia. Transplantation and Cellular Therapy, 2022, 28, 195.e1-195.e7.	1.2	6
1226	A glimpse into what happens after PTCy. Blood, 2022, 139, 479-481.	1.4	0
1227	Myeloablative Conditioning Regimen in Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide in Children With High-risk Hematologic Malignancies. Journal of Pediatric Hematology/Oncology, 2022, Publish Ahead of Print, .	0.6	1
1228	High plasma IL-6 levels following haploidentical allogeneic hematopoietic stem cell transplantation post-transplant cyclophosphamide as predictor of early death and worse outcome. Transplant Immunology, 2022, 71, 101543.	1.2	1
1229	HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?. Frontiers in Pediatrics, 2021, 9, 758680.	1.9	1
1230	Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. Bone Marrow Transplantation, 2022, 57, 532-537.	2.4	6
1231	Established and Emerging Treatments of Skin GvHD. Frontiers in Immunology, 2022, 13, 838494.	4.8	8

#	Article	IF	Citations
1232	What Is the Role of HSCT in Philadelphia-Chromosomeâ€“Positive and Philadelphia-Chromosomeâ€“Like ALL in the Tyrosine Kinase Inhibitor Era?. Frontiers in Pediatrics, 2021, 9, 807002.	1.9	2
1233	Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Advances, 2022, 6, 3378-3385.	5.2	45
1234	HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. Transplantology, 2022, 3, 51-67.	0.6	0
1235	Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients. Transplantation and Cellular Therapy, 2022, 28, 262.e1-262.e10.	1.2	1
1236	Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans. Frontiers in Immunology, 2022, 13, 805177.	4.8	6
1237	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Transplantation and Cellular Therapy, 2022, 28, 265.e1-265.e9.	1.2	6
1238	Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplantation and Cellular Therapy, 2022, 28, 259.e1-259.e11.	1.2	11
1239	Haplo-identical Haematopoietic Stem Cell Transplantation in Refractory Hodgkin Lymphoma After Carmustine, Etoposide, Cytarabine, Melphalan Conditioning Regimen. Touch Reviews in Oncology & Haematology, 2021, 17, 111.	0.2	0
1240	Hematopoietic Stem Cell Transplantation in Nepal: International Partnership, Implementation Steps, and Clinical Outcomes. Transplantation and Cellular Therapy, 2022, 28, 268-275.	1.2	8
1241	Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies. International Journal of Hematology, 2022, 115, 525-533.	1.6	2
1242	Haploidentical hematopoietic stem cell transplantation in pediatric and adolescent patients: A study of the Spanish hematopoietic stem cell transplantation group (GETH). Medicina ClÃnica, 2022, 159, 411-419.	0.6	2
1243	Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry. Cancers, 2022, 14, 1097.	3.7	4
1244	Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT. Transplantation and Cellular Therapy, 2022, 28, 303.e1-303.e7.	1.2	2
1245	Cyclophosphamideâ€induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120Âmg/kg or less. Asia-Pacific Journal of Clinical Oncology, 2022, , e13674.	1.1	6
1246	Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. Transplantation and Cellular Therapy, 2022, 28, 161.e1-161.e10.	1.2	1
1247	Incidence and Outcomes of Respiratory Failure after Nonmyeloablative Related Haploidentical Blood or Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 160.e1-160.e8.	1.2	2
1248	Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, , .	1.2	4
1249	Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 169.e1-169.e9.	1.2	7

#	Article	IF	Citations
1250	Transplantation for Fanconi anaemia: lessons learned from Brazil. Lancet Haematology,the, 2022, 9, e228-e236.	4.6	15
1251	Immune reconstitution and survival of patients with parvovirus B19 related pure red cell aplasia after haplo-PBSCT. Annals of Hematology, 2022, 101, 1333-1342.	1.8	1
1252	Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. Oncology and Therapy, 2022, 10, 105-122.	2.6	2
1253	Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. Transplantation and Cellular Therapy, 2022, 28, 368.e1-368.e7.	1.2	4
1254	Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. Transplantation, 2022, 106, 1279-1287.	1.0	4
1255	Pediatric immune deficiencies: current treatment approaches. Current Opinion in Pediatrics, 2022, 34, 61-70.	2.0	0
1256	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bone Marrow Transplantation, 2022, 57, 949-958.	2.4	7
1257	How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood, 2023, 141, 49-59.	1.4	26
1261	KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection. Frontiers in Immunology, 2022, 13, 821533.	4.8	7
1267	Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 403.e1-403.e7.	1.2	4
1268	Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. Transplantation and Cellular Therapy, 2022, 28, 508.e1-508.e8.	1.2	6
1269	A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant. Transplantation and Cellular Therapy, 2022, 28, 349-354.	1.2	4
1270	Risk factors for adverse outcomes following haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: a two-center analysis. Annals of Hematology, 2022, , .	1.8	0
1272	Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Advances, 2022, 6, 4570-4580.	5.2	17
1273	Need for hemodialysis in patients undergoing hematopoietic stem cell transplantation: risk factors and survival in a retrospective cohort. Hematology, Transfusion and Cell Therapy, 2023, 45, 297-305.	0.2	2
1275	Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants. Haematologica, 2022, 107, 1230-1231.	3.5	3
1276	Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing. Cell Transplantation, 2022, 31, 096368972211029.	2.5	7
1277	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	2.4	10

#	Article	IF	Citations
1278	Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 587.e1-587.e7.	1.2	11
1279	Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2022, 116, 744-753.	1.6	4
1280	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2022, 57, 1421-1427.	2.4	7
1281	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 710.e1-710.e10.	1.2	7
1282	The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation. Leukemia and Lymphoma, 0, , 1-7.	1.3	0
1283	Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. Bone Marrow Transplantation, 2022, 57, 1573-1580.	2.4	8
1284	Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Advances, 2022, 6, 4098-4106.	5.2	9
1285	Current status and prospects of hematopoietic stem cell transplantation in China. Chinese Medical Journal, 2022, 135, 1394-1403.	2.3	7
1286	Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematology,the, 2022, 9, e660-e669.	4.6	22
1287	Haploidentical bone marrow transplantation for severe aplastic anaemia: looking to the future. Lancet Haematology,the, 2022, 9, e629-e630.	4.6	0
1288	A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies. Cell Transplantation, 2022, 31, 096368972211120.	2.5	2
1289	High Risk of Recurrence of Malignancy Noted in 4-day rATG Regimen after Allogeneic PBSCT from Matched Sibling Donors.. Transplantation and Cellular Therapy, 2022, , .	1.2	0
1290	Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation. Bone Marrow Transplantation, 2022, 57, 1681-1688.	2.4	8
1291	Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy. Journal of Clinical Medicine, 2022, 11, 4775.	2.4	1
1292	Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Advances, 2022, 6, 4491-4500.	5.2	9
1293	Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leukemia and Lymphoma, 2022, 63, 2987-2991.	1.3	1
1294	Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. Blood, 2023, 141, 60-71.	1.4	5
1295	The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease. Journal of Clinical Investigation, 2022, 132, .	8.2	5

#	Article	IF	Citations
1296	Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation. International Journal of Hematology, 0, , .	1.6	1
1298	Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies. Annals of Transplantation, 0, 27, .	0.9	1
1299	Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation, 0, , .	2.4	0
1300	Posttransplant cyclophosphamideâ€based antiâ€“graftâ€versusâ€host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigenâ€mismatched unrelated donors versus haploidentical donors: A study on behalf of the <scp>ALWP</scp> of the <scp>EBMT</scp>. Cancer, 0, , .	4.1	1
1301	Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation. Bone Marrow Transplantation, 2022, 57, 1781-1787.	2.4	5
1303	Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. Blood Cancer Journal, 2022, 12, .	6.2	10
1304	Graft-Versus-Host Disease (GVHD) after Post-Transplant Cyclophosphamide or Conventional GVHD Prophylaxis: Same Title, Different Song. Transplantation and Cellular Therapy, 2022, 28, 623-624.	1.2	1
1305	Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review. Frontiers in Oncology, 0, 12, .	2.8	7
1307	Reducedâ€dose postâ€transplant cyclophosphamide plus lowâ€dose postâ€transplant antiâ€thymocyte globulin as graftâ€versusâ€host disease prophylaxis with fludarabineâ€“busulfanâ€“cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. British Journal of Haematology, 2023, 200, 210-221.	2.5	9
1308	A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient. Cell Transplantation, 2022, 31, 096368972211325.	2.5	2
1309	Haploidentical donor the donor of choice in the treatment of relapse Hodgkinâ€™s lymphoma. Medicinski Pregled, 2022, 75, 54-56.	0.1	0
1311	T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy. Frontiers in Pediatrics, 0, 10, .	1.9	2
1312	Cardiovascular Complications in Hematopoietic Stem Cell Transplanted Patients. Journal of Personalized Medicine, 2022, 12, 1797.	2.5	5
1313	Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. HemaSphere, 2022, 6, e790.	2.7	3
1314	Lower intensity regimens for acute myeloid leukemia: opportunities and challenges. Leukemia and Lymphoma, 2023, 64, 66-70.	1.3	0
1315	Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD. Blood Advances, 2023, 7, 4886-4902.	5.2	6
1316	Ex vivo and in vivo T-cell depletion in allogeneic transplantation: towards less or non-cytotoxic conditioning regimens. Expert Review of Clinical Immunology, 2022, 18, 1285-1296.	3.0	2
1317	Haploidentical hematopoietic stem cell transplantation in pediatric and adolescent patients: A study of the Spanish hematopoietic stem cell transplantation group (GETH). Medicina ClÃnica (English) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	1

#	Article	IF	Citations
1318	Cytokine Release Syndrome and Sepsis. Infectious Disease Clinics of North America, 2022, 36, 735-748.	5.1	4
1319	Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation. Bone Marrow Transplantation, 0, , .	2.4	0
1320	Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. Frontiers in Immunology, 0, 13, .	4.8	3
1322	Haploidentical bone marrow transplants with post transplant cyclophosphamide on dayÂ+Â3Â+Â5: The Genova protocol. Blood Reviews, 2023, 62, 101031.	5.7	5
1323	A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donorsâ€"A singleâ€centre, prospective, explorative study. British Journal of Haematology, 0, , .	2.5	0
1325	The development of post-transplant cyclophosphamide: Half a century of translational team science. Blood Reviews, 2023, 62, 101034.	5.7	1
1326	Impact of posttransplant cyclophosphamide on the outcome of patients undergoing unrelated single-unit umbilical cord blood transplantation for pediatric acute leukemia. BMC Cancer, 2022, 22, .	2.6	0
1327	Antithymocyte Globulin Plus Post-Transplant Cyclophosphamide Combination as an Effective Strategy for Graft-versus-Host Disease Prevention in Haploidentical Peripheral Blood Stem Cell Transplantation for Children with High-Risk Malignancies. Pharmaceuticals, 2022, 15, 1423.	3.8	1
1328	Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors. Cell Transplantation, 2022, 31, 096368972211391.	2.5	3
1329	Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplantation and Cellular Therapy, 2023, 29, 71-81.	1.2	10
1330	Controversies and expectations for the prevention of GVHD: A biological and clinical perspective. Frontiers in Immunology, 0, 13, .	4.8	5
1331	First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens. Bone Marrow Transplantation, 0, , .	2.4	0
1333	Anti-Thymocyte Globulin (ATG)-Free Nonmyeloablative Haploidentical PBSCT Plus Post-Transplantation Cyclophosphamide Is a Safe and Efficient Treatment Approach for Pediatric Acquired Aplastic Anemia. International Journal of Molecular Sciences, 2022, 23, 15192.	4.1	0
1334	Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide. Pharmaceuticals, 2022, 15, 1529.	3.8	2
1335	Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2023, 29, 181.e1-181.e10.	1.2	4
1336	Hematology 2022â€"what is complete HLA match in 2022?. Hematology American Society of Hematology Education Program, 2022, 2022, 83-89.	2.5	9
1337	New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT). Hematology American Society of Hematology Education Program, 2022, 2022, 74-82.	2.5	4
1338	Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Advances, 2023, 7, 2018-2031.	5.2	8

#	Article	IF	Citations
1339	Effective Tâ€cell replete haploidentical stem cell transplantation for pediatric patients with highâ€risk hematologic disorders. European Journal of Haematology, 0, , .	2.2	1
1340	Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. , 2023, 40, .		3
1341	Selected memory T cells infused post haploidentical hematopoietic stem cell transplantation persist and hyper-expand. Blood Advances, 0, , .	5.2	1
1342	Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	1
1343	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source. Transplantation and Cellular Therapy, 2023, 29, 267.e1-267.e5.	1.2	2
1344	Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas. Transplantation and Cellular Therapy, 2023, 29, 184.e1-184.e9.	1.2	5
1345	Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis. Annals of Hematology, 0, , .	1.8	0
1346	Don't forget cord blood in nonâ€remission <scp>acute myeloid leukaemia</scp> !. British Journal of Haematology, 0, , .	2.5	0
1347	Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro. Bone Marrow Transplantation, 2023, 58, 407-413.	2.4	1
1348	Human Leucocyte Antigen System and Selection of Unrelated Hematopoietic Stem Cell Donors: Impact of Patientâ€“Donor (Mis)matching and New Challenges with the Current Technologies. Journal of Clinical Medicine, 2023, 12, 646.	2.4	2
1349	Impact of Post-Transplantation Cyclophosphamide on Transfusion Requirements in HLA-Matched Sibling Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2023, 29, 313.e1-313.e10.	1.2	4
1350	Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells. Blood Advances, 2023, 7, 2431-2435.	5.2	3
1351	Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transplantation, 2023, 58, 386-392.	2.4	15
1352	Unrelated Donor Cord Blood Transplantation in Children: Lessons Learned Over 3 Decades. Stem Cells Translational Medicine, 2023, 12, 26-38.	3.3	4
1353	Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond. Blood Reviews, 2023, , 101053.	5.7	0
1354	Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis. HemaSphere, 2023, 7, e846.	2.7	1
1355	Sequence matters: Total body irradiation (TBI)â€based myeloablative conditioning with postâ€transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus <scp>TBI</scp>. European Journal of Haematology, 0, , .	2.2	0
1357	Haploidentical Î³Î´ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma. Journal of Immunotherapy, 2023, 46, 56-58.	2.4	3

#	Article	IF	Citations
1358	A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant. Transplantation and Cellular Therapy, 2023, , .	1.2	0
1359	Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation. Blood Advances, 2023, 7, 2888-2896.	5.2	0
1360	NCCN GuidelinesÂ® Insights: Hematopoietic Cell Transplantation, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 108-115.	4.9	3
1361	Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2023, 58, 552-557.	2.4	2
1362	Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience. Transplant Immunology, 2023, 77, 101808.	1.2	0
1363	Recent advances in graft-versus-host disease. Faculty Reviews, 0, 12, .	3.9	0
1364	Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2023, 29, 346.e1-346.e10.	1.2	13
1365	Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of Hematology and Oncology, 2023, 16, .	17.0	0
1366	The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation. International Journal of Molecular Sciences, 2023, 24, 5764.	4.1	3
1367	Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy. Frontiers in Immunology, 0, 14, .	4.8	3
1368	Adverse impact of a high <scp>CD4</scp>/<scp>CD8</scp> ratio in the allograft may be overcome by methotrexateâ€•but not mycophenolateâ€•or postâ€transplant cyclophosphamideâ€based graft versus host disease prophylaxis. European Journal of Haematology, 2023, 110, 715-724.	2.2	2
1370	Addition of ATG to non-myeloablative peripheral blood haploidentical transplant with PTCY decreases acute GVHD rates and improves GVHD-relapse free survival. Bone Marrow Transplantation, 0, , .	2.4	0
1372	Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification. Blood Reviews, 2023, 62, 101078.	5.7	2
1373	Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Stem Cell Investigation, 0, 10, 8-8.	3.0	0
1375	Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies. Blood Reviews, 2023, 62, 101080.	5.7	8
1376	Principles of Conditioning Therapy and Cell Infusion. , 2023, , 91-99.		0
1377	Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature. Transplantation and Cellular Therapy, 2023, 29, 473.e1-473.e6.	1.2	2
1378	Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide. Annals of Hematology, 2023, 102, 1561-1567.	1.8	5

#	Article	IF	Citations
1379	Modern methods of therapy in the development of life-threatening complications in a patient after repeated allogeneic hematopoietic stem cell transplantation: review of the literature and clinical case. Russian Journal of Pediatric Hematology and Oncology, 2023, 10, 57-67.	0.3	0
1380	Postâ€transplant cyclophosphamide as sole GHVD prophylaxis after matched reducedâ€intensity conditioning allotransplant. Clinical and Translational Medicine, 2023, 13, .	4.0	0
1381	Impact of cytomegalovirus immunodominant HLAâ€donorâ€“recipient matching on the incidence and features of virus DNAemia and virusâ€specific Tâ€cell immune reconstitution in unmanipulated haploidentical hematopoietic stem cell transplantation. Transplant Infectious Disease, 2023, 25, .	1.7	0
1382	Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model. Experimental Hematology, 2023, 123, 56-65.	0.4	1
1383	Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation. Transplantation and Cellular Therapy, 2023, , .	1.2	0
1384	Posttransplant cyclophosphamide vs tacrolimusâ€“based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Advances, 2023, 7, 3903-3915.	5.2	5
1385	NK cell defects: implication in acute myeloid leukemia. Frontiers in Immunology, 0, 14, .	4.8	4
1386	Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemiaâ€a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2023, 58, 907-915.	2.4	2
1387	Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2023, 36, 101475.	1.7	0
1388	Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2023, 29, 515.e1-515.e7.	1.2	1
1389	Cyclophosphamide with cyclosporine A for graft-versus-host disease prophylaxis in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation from human leucocyte antigen-matched donors. International Immunopharmacology, 2023, 120, 110374.	3.8	1
1390	Acute Graft-versus-Host Disease: An Update on New Treatment Options. Drugs, 2023, 83, 893-907.	10.9	2
1391	Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 0, , .	2.4	1
1392	Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Advances, 2023, 7, 5639-5648.	5.2	4
1393	Case Series Using Salvage Haplo-Identical Stem Cells for Secondary Transplantation. Medicina (Lithuania), 2023, 59, 1077.	2.0	0
1394	The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2023, , 101485.	1.7	0
1395	Acute graft-versus-host disease. Nature Reviews Disease Primers, 2023, 9, .	30.5	19
1396	Graft versus Leukemia in 2023. Best Practice and Research in Clinical Haematology, 2023, 36, 101476.	1.7	1

#	Article	IF	Citations
1397	Haploidentical stem cell transplantation with post-transplant cyclophosphamide challenges and outcome from a tertiary care center in Lebanon. , 0, 2, .		1
1398	An Overview of Graft-Versus-Host Disease. , 2023, , 17-44.		0
1399	Hematopoietic Stem Cell Transplantation: An Overview. , 2023, , 1-15.		0
1400	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. New England Journal of Medicine, 2023, 388, 2338-2348.	27.0	64
1401	Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight. Blood Reviews, 2023, 62, 101093.	5.7	1
1403	Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation. Scientific Reports, 2023, 13, .	3.3	1
1404	Successful treatment of DOCK8 deficiency by allogeneic hematopoietic cell transplantation from alternative donors. International Journal of Hematology, 0, , .	1.6	0
1405	Graft-Versus-Host Disease. , 2024, , 453-479.		0
1406	Hematopoietic Cell Transplantation for Hodgkin Lymphoma. , 2024, , 357-370.		0
1407	Hematopoietic Cell Transplantation in Adult With Acute Myeloid Leukemia. , 2024, , 183-204.		0
1408	Hematopoietic Transplantation: Past, Present, and Future. , 2024, , 3-16.		0
1409	Haploidentical Hematopoietic Cell Transplantation. , 2024, , 83-100.		0
1410	Non-Expressed Donor KIR3DL1 Alleles May Represent a Risk Factor for Relapse after T-Replete Haploidentical Hematopoietic Stem Cell Transplantation. Cancers, 2023, 15, 2754.	3.7	0
1411	Editorial: Controversies and expectations for prevention and treatment of graft-versus-host-disease: a biological and clinical perspective. Frontiers in Immunology, 0, 14, .	4.8	0
1412	Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT. Blood, 2023, 142, 477-492.	1.4	7
1413	An analysis of the efficacy of graft-versus-host disease prophylaxis with post-transplant cyclophosphamide in children with acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation from HLA-matched and partially-matched unrelated donors. Pediatric Hematology/Oncology and Immunopathology, 2023, 22, 32-43.	0.3	0
1414	Posttransplant cyclophosphamide beyond haploidentical transplantation. Annals of Hematology, 0, , .	1.8	1
1415	Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT. HemaSphere, 2023, 7, e920.	2.7	0

#	Article	IF	Citations
1416	First Sips From the Holy Grail?. Transplantation, 0, Publish Ahead of Print, .	1.0	0
1417	Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration. Haematologica, 2023, 108, 3321-3332.	3.5	3
1418	Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2023, 29, 581.e1-581.e8.	1.2	0
1419	Allogeneic haematopoietic cell transplants as dynamical systems: influence of earlyâ€term immune milieu on longâ€term Tâ€cell recovery. Clinical and Translational Immunology, 2023, 12, .	3.8	0
1420	Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections. Transplant Infectious Disease, 2023, 25, .	1.7	2
1421	Clinical features and outcomes of patients admitted to the ICU for Cyclophosphamide-associated cardiac toxicity: a retrospective cohort. Supportive Care in Cancer, 2023, 31, .	2.2	0
1422	Early cessation of calcineurin inhibitors is feasible postâ€“haploidentical blood stem cell transplant: the ANZHIT 1 study. Blood Advances, 2023, 7, 5554-5565.	5.2	3
1423	Novel developments in the prophylaxis and treatment of acute GVHD. Blood, 2023, 142, 1037-1046.	1.4	4
1424	Haploidentical Stem Cell Transplant. , 2023, , 551-570.		0
1425	Post transplant Immunosuppression. , 2023, , 695-704.		0
1426	Classification of Conditioning Regimens. , 2023, , 183-202.		0
1428	O Brother, Where Art Thou?. , 2023, , 119-123.		0
1429	Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide. International Journal of Hematology, 2023, 118, 347-354.	1.6	0
1430	Graft-versus-host disease: teaching old drugs new tricks at less cost. Frontiers in Immunology, 0, 14, .	4.8	1
1431	Abatacept and T-cell costimulation blockadeâ€”shifting the paradigm in the prevention of graft-versus-host disease. , 0, 2, .		1
1432	GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2023, 58, 1179-1181.	2.4	1
1433	<scp>ATG</scp> versus <scp>PTCy</scp> in matched unrelated donor haematopoietic stem cell transplantations with nonâ€myeloablative conditioning. British Journal of Haematology, 0, , .	2.5	1
1434	Existence of HLA-Mismatched Unrelated Donors Closes the Gap in Donor Availability Regardless of Recipient Ancestry. Transplantation and Cellular Therapy, 2023, 29, 686.e1-686.e8.	1.2	4

#	Article	IF	Citations
1435	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	5
1436	Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplantation, 2023, 58, 1215-1222.	2.4	4
1437	Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT. Bone Marrow Transplantation, 0, , .	2.4	0
1438	Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. Cell Transplantation, 2023, 32, .	2.5	1
1439	Results From the Blood and Marrow Transplant Clinical Trials Network: How Should We Prevent Graft-versus-host Disease in 2023?. , 2023, 20, .		0
1440	Targeted dosing of antiâ€thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A singleâ€arm, phase 2 trial. American Journal of Hematology, 2023, 98, 1732-1741.	4.1	1
1441	Prospective analysis to determine barriers to <scp>allogeneic hematopoietic cell transplantation</scp> in patients with acute leukemia. American Journal of Hematology, 0, , .	4.1	0
1442	Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?. Hematology, 2023, 28, .	1.5	1
1443	Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir. Bone Marrow Transplantation, 2023, 58, 1104-1111.	2.4	2
1444	Graft conditioning with fluticasone propionate reduces graftâ€versusâ€host disease upon allogeneic hematopoietic cell transplantation in mice. EMBO Molecular Medicine, 2023, 15, .	6.9	0
1445	Improving Outcomes with Haploidentical Stem Cell Transplantation [HaploSCT] in Children Using Post-transplant Cyclophosphamide: a Single Center Experience. Indian Journal of Hematology and Blood Transfusion, 0, , .	0.6	0
1446	The two-step approach to allogeneic hematopoietic stem cell transplantation. Frontiers in Immunology, 0, 14, .	4.8	0
1447	Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm. Bone Marrow Transplantation, 2023, 58, 1121-1129.	2.4	0
1448	Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia. Transplantation and Cellular Therapy, 2023, 29, 766.e1-766.e8.	1.2	1
1449	Hepatic graft-versus-host disease: what we know, when to biopsy, and how to diagnose. Human Pathology, 2023, , .	2.0	0
1451	Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2023, 129, 3735-3745.	4.1	1
1452	Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. HemaSphere, 2023, 7, e952.	2.7	1
1454	Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT). Transplantation and Cellular Therapy, 2024, 30, 93.e1-93.e12.	1.2	2

#	Article	IF	Citations
1455	Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation, 0, , .	2.4	0
1456	Recent advances in allogeneic transplantation for acute myeloid leukemia. Current Opinion in Oncology, 2023, 35, 564-573.	2.4	1
1457	Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era. Hematology, Transfusion and Cell Therapy, 2023, , .	0.2	0
1458	A new sequential conditioning regimen based on CPX- 351/Vyxeos (â€œVyx-Seqâ€) in patients with higher risk myelodysplastic syndromes. Leukemia Research, 2023, 135, 107405.	0.8	0
1459	Hottest topics in hematopoietic stem cell transplantation: a summary from the 8th International Transplant and Cellular Therapy Course. Clinical Hematology International, 2023, 5, .	1.7	3
1460	Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?. Expert Review of Hematology, 2023, 16, 905-910.	2.2	0
1461	Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplantation, 2024, 59, 76-84.	2.4	1
1462	The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation. Expert Review of Hematology, 2023, 16, 943-962.	2.2	1
1463	Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome. Bone Marrow Transplantation, 0, , .	2.4	2
1464	Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age. Annals of Hematology, 0, , .	1.8	0
1465	PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphomaâ€”A Matched-Pair Analysis. Cancers, 2023, 15, 5246.	3.7	0
1466	Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study. Frontiers in Immunology, 0, 14, .	4.8	1
1467	Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy, 2023, , .	0.7	0
1468	Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study. Bone Marrow Transplantation, 2024, 59, 232-238.	2.4	0
1469	Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study. Current Oncology, 2023, 30, 9953-9967.	2.2	0
1470	Hematopoietic Cell Transplantation. , 2023, , 23-36.		0
1471	Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience. Annals of Hematology, 0, , .	1.8	1
1472	Explorations of post-gDLI low-dose cyclophosphamide for preventing severe aGVHD. International Immunopharmacology, 2023, 125, 111165.	3.8	0

#	Article	IF	Citations
1473	Targeted Radiation Delivery Before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-Term Survivors. Clinical Cancer Research, 0, , .	7.0	0
1474	Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis. Cytotherapy, 2023, , .	0.7	1
1475	Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2024, 30, 229.e1-229.e11.	1.2	0
1476	Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplantation and Cellular Therapy, 2024, 30, 233.e1-233.e14.	1.2	1
1477	Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry. Transplantation and Cellular Therapy, 2023, , .	1.2	0
1478	HLA Haplotypes and Relapse After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2024, 42, 886-897.	1.6	0
1479	Approaches to optimize outcomes in transplant recipients. Hematology American Society of Hematology Education Program, 2023, 2023, 723-730.	2.5	0
1480	Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematology American Society of Hematology Education Program, 2023, 2023, 164-170.	2.5	0
1481	The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally. Hematology American Society of Hematology Education Program, 2023, 2023, 532-541.	2.5	0
1482	Lowâ€versus standardâ€dose postâ€transplant cyclophosphamide as <scp>GVHD</scp> prophylaxis for haploidentical transplantation. British Journal of Haematology, 0, , .	2.5	0
1483	Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2024, 30, 210.e1-210.e14.	1.2	0
1485	Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor. Bone Marrow Transplantation, 2024, 59, 344-349.	2.4	0
1486	HÃmatopoetische Stammzelltransplantation: seit Jahrzehnten etablierte Zelltherapie. , 2023, , 161-181.		0
1487	Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide â€“ A retrospective single-center study with a Japanese cohort. Blood Cells, Molecules, and Diseases, 2024, 105, 102820.	1.4	0
1488	Kidney transplantation: Assessment of the Kidney Donor Candidate. , 2024, , 255-409.		0
1489	Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia. International Journal of Molecular Sciences, 2024, 25, 957.	4.1	0
1490	Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics, 2024, 25, 29-40.	1.3	0
1491	Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation. Leukemia and Lymphoma, 2024, 65, 493-502.	1.3	1

#	Article	IF	Citations
1492	Individualized rabbit antiâ€thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with highâ€risk hematologic malignancy: Exposureâ€“response analysis and population pharmacokinetics simulations. American Journal of Hematology, 2024, 99, 387-395.	4.1	0
1493	Phase <scp>I</scp> study of zoledronic acid combined with escalated doses of interleukineâ€2 for early in vivo generation of <scp>Vδ39Vγ2 T</scp>â€cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. American Journal of Hematology, 2024, 99, 350-359.	4.1	0
1494	Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2024, 59, 373-379.	2.4	0
1495	Myeloablative Haploidentical Donor Hematopoietic Transplantation Using Post-Transplantation Cyclophosphamide and Antithymocyte Globulin. Transplantation and Cellular Therapy, 2024, 30, 312.e1-312.e7.	1.2	0
1496	Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry. Journal of Hematology and Oncology, 2024, 17, .	17.0	0
1497	Persistence of KIRneg NK cells after haploidentical hematopoietic stem cell transplantation protects from human cytomegalovirus infection/reactivation. Frontiers in Immunology, 0, 14, .	4.8	0
1498	How adoptive transfer of components of the donor immune system boosts GvL and prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute leukemia. Bone Marrow Transplantation, 2024, 59, 301-305.	2.4	0
1499	How does ocular graftâ€versusâ€host disease fit under the dry eye umbrella? A review. Clinical and Experimental Ophthalmology, 2024, 52, 167-185.	2.6	0
1500	Graft-versus-host disease after an outpatient peripheral blood hematopoietic cell transplant using reduced-intensity conditioning: a single-center LATAM experience. Expert Review of Hematology, 2024, 17, 77-86.	2.2	0
1501	Acute graft versus host disease 1976â€“2020: reduced incidence and predictive factors. Frontiers in Medicine, 0, 10, .	2.6	0
1502	Reduced Cytokine Release Syndrome and Improved Outcomes with Earlier Immunosuppressive Therapy in Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2024, 30, 438.e1-438.e11.	1.2	0
1503	Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers, 2024, 16, 532.	3.7	0
1505	Human Leukocyte Antigenâ€“Haploidentical Haematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide for Paediatric Haematological Malignancies. Cancers, 2024, 16, 600.	3.7	0
1506	Janus kinase inhibition in the treatment and prevention of graft-versus-host disease. Frontiers in Immunology, 0, 15, .	4.8	0
1507	Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transplantation, 2024, 59, 597-603.	2.4	1
1508	Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era â€“ forgotten but not gone. Leukemia and Lymphoma, 0, , 1-10.	1.3	0
1509	More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?. Hematology, 2024, 29, .	1.5	0
1512	Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer Journal, 2024, 14, .	6.2	0

#	Article	IF	Citations
1513	Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. Cytotherapy, 2024, , .	0.7	0
1514	Breaking Human Leukocyte Antigen-related Barriers in Allogeneic Hematopoietic Cell Transplantation. , 2024, 21, .		0
1515	Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort. Transplantation and Cellular Therapy, 2024, 30, 544.e1-544.e8.	1.2	0
1516	Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain. American Journal of Hematology, 2024, 99, 922-937.	4.1	0
1517	Unlocking Insights. Oncology Times, 2024, 46, 1,6,7,11-11.	0.1	0
1518	The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients. Expert Opinion on Biological Therapy, 2024, 24, 139-146.	3.1	0
1519	Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplantation, 0, , .	2.4	0
1520	2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. American Journal of Hematology, 2024, 99, 938-945.	4.1	0
1521	Graftâ€versusâ€leukaemia immunity is retained following treatment with postâ€transplant cyclophosphamide alone or combined with tocilizumab in humanised mice. Clinical and Translational Immunology, 2024, 13, .	3.8	0
1522	Recent advancements in hematopoietic stem cell transplantation in Taiwan. Tzu Chi Medical Journal, 2024, 36, 127-135.	1.1	0
1524	<scp>HLA</scp>â€haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of <scp>EBMT</scp> severe aplastic Anemia and pediatric diseases working parties. American Journal of Hematology, 0, , .	4.1	0
1525	Current status of conditioning regimens in haploidentical hematopoietic cell transplantation. Hematology, 2024, 29, .	1.5	0